var title_f19_35_20016="Classic achalasia Ba swallow";
var content_f19_35_20016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Achalasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 395px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGLAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6Z8PWK6ZoVhZICohhVMH1xz+taFFFAAQDnIHPBoAwMDpRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeN/HrwXZXukyatDHtuhwwUdeOteyVjeL4o5vD14koByhAOOlAHwJqg8mN0Oc5A545rmXwGOM/TGMc12fjaNI9SuI4pA2xjnnHGev61xwHlykSgFs5yTxQAkAzKAFDeoNWrslIlVRx3/AAp0UsZ2gfePIGOlM1JizKScg+vX86AKJGcckVFMny5AjwMff6USSqVLJhivvwD0prvsCKTuYY554NAFORNhIzkgkYxTSMHB61M6oJ3Dl9uevv8A5zUJAycHP9aAEooooAKKKKACiiigAooooAKKKKACiiigD9VKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKxfGUgh8NX0jEALGTz3rarhvjJqqaZ4Hvs5Mki7QB6UAfEPii7abVbt8KDvxx2561zscjohCsQvfHrVrVi/2lyzZDE8A+9UaALKRyl/4gDyTyOtJczM5KjKqMfKetLDO4H3SQMZ9gKq3LFiz79o6k4oAVvmOe+c9KgmUNnBwd2D+Ix/Wq0kkgALEhjyDntj8qi3N/ePTHXt6UAKxcbgWPB5Ge9DA8FlIB6U3PGO1JQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB+qlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfOn7THiH7RcW+j2jANFzJ83JNfQt9OLaznnY4EaFs/QV8TeNtQfV/FF5dvIzDzCAT3HY0Aeb61AdwlAzn09KyTXT6hGZ42yCX5+7j8a5xhhiHYZTj1zQA3ACnPJx+v/AOqq87AKwBGTwenXHerKruzkHPByOmPWqV0VDkleSPoCaAKpORgZx3yfSmn04OPSpZkVdrKCFbPynqMVDQAUUvGPekoAKKKKACiiigAooooAKKKKACiiigAooooA/VSiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOJ+MOuRaD4Ev7mTO518tADjkivjFr55d8pUfOdwPua9j/ao8UtcahFoEMp8mIBpExwWrwGKcgBAzbh0Awc0Aa5hBtAw5PUjsa5W+h/fEpz1J59K6zTX8x+VbJHAPBHPSqGs6euPkAU89R3oA5pRkAsMLnrjtUMwQFm4Ckbcn0q2kaFArFlfnIPas6/cfcGQOo9/rQBXnCHDIV57D/PFRce9JRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfqpRVTSL1NS0qzvY8bLmFJlx6MoP8AWrdABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4/wDGT4u23hN5dI0wGbVmXBYHiIn+tewV8zftAeApLfULnXrRXMUrbn44B69aAPDNX1C51S7udRvHeSec5LHOd2ef6VkQx7ZSzK5ZemBnFXrmbZF8u3PQGqRmLNlcjB7NQBuaVcsTEHUADn+tXdXVJUYqwA25yPWsaKQ/fzjaepGOR3onuwWxJ8uAcADsKAMq7DQRMTjOOCD+tctNjzXKnIJzmuqvDvjkYlSMHAH88VykxzK5IxyaAGUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH6H/ALP2uLr3wm0GfOZIIfs0n+8nH8sV6LXy/wDsVeJlk0/WfDc0g3xOLuBSex4bH6GvqCgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4L43uifDrUd4BzjAPr1rva8i/aQ1a1tPCC2Ukw8+duIgeSvrQB8Yz75iRIGxnjaetP0+3BOXkPA556CtttH8yHK7Rj72e2e3vUY0mWJV8rqTwQKAIBJiNBCrEd8DOB/jUMsrbVYkCQ+nHy4q79kkiHIPLZ+Xp9MCoZyY35ACMuDkYz+IoAzLkqsBy3JBFczIEU4UkkdeMc1v6pLySTnHJxiudPX0oASiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA9F/Z/8Rp4Y+Kmi3dxI0dtLJ9mlIPGH+Xn86/Q+vytjdo5FdCVdSCCOoNfol8C/GEfjT4c6ZfeZvu4EFtcg9fMQAZP1GDQB6BRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV88ftLaBNdarZ6g+42wj28DIBBr6HrnfH+nRal4WvY5kViiFlJ7H2oA+N4YIvJX5cggdaglu/Jl2AjHOM1dLoJZkXaAjHvz71m6hFHJIAMAY4K8daAGXT/ahkqm4NnIHFYmsuHkAAO5ePwrQ1CZoIcoQODWDNIZptzHgnH4UAZGpBtzbSAxHBxisu4RVCkdejAcc1r6g4D8AFgOg6k1hszMcsST0oAbRRRQAUUUUAFFFFABRRTkUswA70ANpwUkZ7e9TSW5UrkgZ6knjNK8bIgVNrA8nAB/z3oAr4/SkpeQO4B/Wg+1ACUUUUAFFFFABXun7KHj1PDHjR9H1G48vTNWAQFj8qTD7p/HkfjXhdPjdopEkjYq6EMrA4II6GgD9UaK83+AHjRvG3w4sLu5cNqFqPs1zzkll4DH6j+tekUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcn8T9Yi0bwheyzMo8xSg3H1rrK+R/jn4p1XxJrj2tvbzx2Fs5UBshWxQB59a3Yaec5YhmJO45yDSygOvOdrdR0FVrONkJeRdr9NuOlaaIs867mB+UEkDr9aAMHUm3gxgkqO3XmsK43xgfI2T145Arr5rVPMkbZwTjr79ayby2Tz+QeOn0oA46+EjsQu7KnOSeeOMcd6qpaM2CWAH45rZ1GNUuDg+o/KqgAHSgCjLbiNMlvxJ4qGRQrYU5XGQfWr1wispZsEgHAOapS5ODgAdAfXFAEdFFFABTlUsQB9KfHC7EZVgp74q7HGFUAonXPHagCtHbFkbfuVu3SrKIkeGC4AH3jUn8Q5/CmNvLYxlSR+XegBJgp5O0lezdB71UkkUlioGCOnIx2qabYNzFSWbjrjFVgg/vAg/5yfQUAOELGIOvPBJ9sVEATnAJxzVgKsYIZgwLYxzzikIJ3tF9xuPU9M0AV6Ke4wTwRjg/Wmng0AJRTs/KB2FFADaKKKAPdP2UPHieGPGj6PfyFbDV9sYJPEco+6fx6V9wV+WFrPJa3MU8DlJYmDow7EHINfoD8BfiVb/ABC8JxmZ1XWrJVjvIyeWOOJB7H+dAHp1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZd/oGl37Frqyhdj1O0ZNalFAHi/xJ+EtjPZTX2jqYnjUuYx/+rmvntUktbueGQfOmQV6ZIr7rIDAhgCDwQe9fHfxF09LDxxfoMLmQlVA470AcU2Vm2MMHH19KoXufP6DBFa16Ntxnn5gPwqtJEJBuK528k4/SgDmNVCAhWyAwAGPWsWt3VwVkbarjbwOM5OawjyaAGyBShD4298nFZrcA7hz9MYOatXMjAlWChR6Hkg8VT7UAJU9tGzPnbwMcntT7aDLEyA/L2IrRhh3n5QQOmQKAGIpOAAeeBmn7cbhwCODnn8P51ehiCKTtI5z1zjimzBmkXKttU5BUjr9KAKOM5/vdcYptWJo3VQVQqp4IBzUSJubAzjtkdaAIJIlkyT97GAc9KR40OWYEbRjI7d+KuJGvf74ONjcbvT6UGBsZZcE8ADuaAKfkjaqtlgM5yfXvSEOrghFxwvB6Dv+FTHg0gAAwPrQBUSInIQFVzhgcZ/+vx/Oo7pNpGCCB8o9R3/rWh360woCxYqCcY69qAM+SMoo3Fck8Adx60VPeqFxgY3Hn3/zmigCpRRRQAVv+CPFeqeDPENtq+iztFcQsNy5+WRe6sO4NYFFAH6SfC/x7pnxA8Nw6lp0ircBQLm2z80L9x9PQ12Ffmj4A8a6x4G1+HVNEuGjZWHmxE/JKueVYd8199/Cz4haT8Q/Dyajpb+XcIAtzasfnhf09x6GgDs6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAbLIkUTySMFjQFmY9AB1NfGvxE1qPXPGl5d2hHkeaURscHmvf/AI33962hf2TpTt51zxIE67a8DXwRqlk4aaBlUDngk/yoA5rXAYLASMF56ZrEs7liybyWD44JrtPFGmyC1KOhwFydw/HpXCsGWUrnGONw7H/P8qAItejSRsYbIHJHb/PFc06FWJCgqpwSM4NbetSHysBs5zndWEXYrtLHH1oAo3akljgnpzjp7frSwwtkMyqRk8EDp/ntUssW91IY+4z1FTW0B4jQ5PUk0AWrS32jcVIbqCefzq/AgTptJGThjnsTRbXMYVI5VUlRnGPu57VbUxbVKYVhkqGOKAK08YRhgHkc+mfaoWG5SMD8RkVpTDeyIRk9TwcEd6rz2+0gx5IJx9DQBR2YG3AcDru65qMQDJHI4wFPf8fT2q1sKkjGD3zS44GAc9aAIgqvkkMMqRyOeac6llPQqcA07aWYAZz6etIenHWgCusQOVwDt/76HpzVWaPy246HpnqK0xgg81BLEsr4IAxzkdT9aAM+kHyg5Pqcmp54yrHnJ4yO/TrURGCR1x3FAFG5GGDx5O4dcH0/w/lRU8se9hz3HUZooAzqKKKACiiigArqvhz431XwH4ih1XSJMEfLLEfuyp3UiuVooA/Sf4a+PNJ8feH49R0mZTIABPAT80TehHp6Gutr82/hh421bwN4lh1HSJGKk4mgJ+WVfQivvX4d+PtJ8b6Yk9i/lXYX97aycOh749R70AdfRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAU5tNtZ7sXMsQeUDAJ7VLJZ20kZR4Iih6jaKnooA4Xxj4CstUtJDYwpHIVIKAcH3FfKXjnwpeaNqUkUtuQNxwWGRX3PXN+MvCdl4msylwiidR8r4/Q0Afn3q+8IqlmbGMnGKyEJI+bbnPY16X8WfC0nh7W57eJeOc54NeaIixjCLj6UASohdioGT9au2tuUbI3Fj0GKZayl2YYwvUD09q0YE3Y2jBxwc45z/hQBXZCrtwAeh4px+UoylgevIqw4EchLbgSTk4GD9Pbmo1kVFOFyw6MR0oAeLr+8isSMHt+FKUlYB42YqRxz056VCAWfkZLH1xU1uJE8wYJK4+X/AD/KgCBAVccAt1AIzmpGUiQJINoZtx5yRVtDHNuKgZ6Zxz9aJYiUwcbxwTjnHpQBSUbC/wA2GX07npTWjIJ25ZRnke1WRG06Z3YUdFGCOn1qSGEpj5R2Jzz+VAFNFLK+1d2BnPTFRkD8qtzRMzkkgjO3PPA65omjGF2gM33AB0FAFFokIClcjqcnnP8Ak1BNARkxgDsQOc/561pNGm75vMB4yCO+fWnFd8bmZsdxxg+nI/L86AOfdeoP6H/Cir9zbbmLKOSOMDGfeigDnREW+4VY+gqRbaQk5wPrU1kwKkAAEdcD9c1aHPGOT0oAyWG1iD1BxTa0poA7ZbIPQ8f55qnOix4Ufe5z/SgCGilIwcHrSUAXNKlEN2rEA+1dvHrmo6eI7nSrmS0nU5VonwRjtXn0bbXVskYPat2xvg0eHGF7EjpQB9GfC79oq5tmh0/xqrXEf3RdqPnX/e9f519IeGvE+jeJrXz9E1CC7TGWCN8y/Uda/O6GIySlkw+c8gfh/k1o6Rf3+nXsdxpl5PaTIch4n20AfozRXzJ4A+NutWNvFbeIYxqaf89vuyBfc9/xr3Pwv478P+I40FjqEK3LDm3kYK4Ppg9fwoA6iiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+V/2nrVI/FKyANl4gQDwGJ64r5xmQJclSOM9Mf0r6v/ap00/8S7UmOI1Qx569Of618tXDhpx+7V2bJ5GD3oAfCu1VLj5sDdjqavWYBWTG76A/1qoExGCB8o461ZiG4sEAUg4ypPQ/5/lQAjQhNm8tjIznoOMmojE4LDaeBk/Sr7x7lwGIHuM/zpDGu0567cF/UUAUkQuvDgAcHPAFSxu4JQNlBzlR/L8eKmRtrhCMsBlunH4VIIl2rt+UA5AHH50AVjmJQ8YIY/eX1HPJHapknG0mTgZ4I5GKndWC8qRkcZ4zVaSMlCSMeiryD/k0ATlFL5UFcdOfzoAKkhsDsB3qJMJkLnCkBgF6n1/z6Vet3R4iJSAo6cc85oAhVSxwvJ9KiWPazMMknjJ5x7VZni2DKncnqO1RHjggg96AGIAny565I/z+NV5cZDRKSRjhfTH6cfyq0T14NNI2qWJwCc5PSgCjcRney8sBwBjtRUokMqkSYXnBzkYHH60UActaKBHyvOevr3Bq0o2P84OAcHnFRgEcHp2pxxgY/GgCSWQOFIAGBjb2+oqI8irbp/o/3VbaOCOo+tVygxlTkAcn3oAoT26pj72AOuP51BJEyMVPJAzxWnUc0SyLggZ7HHSgDPRd2csAPc1et0Kljng9AOn1psdqAwxkt2+tbVpYhmXdgnv3A/CgCTRkcHLIdp5Dfh/n866GC1HDZH3skAdaigs2WMIF29wx7/WrtrCIvvnJJ5x6UAa1qgSABSOe61mymRJBJbSMsmchwcEfWtDzQsR8shgijrVSZ97bjjd3x0oA7fwh8X/EvhgpBPM2pWKkZW4ySB6K3UdfWvo/4f8Aj7SPGtl5mnv5dyoy9u5G4e49RXxg0bGTr8nUgnOauaRqd9oeoR32mXEkMyMCNrYHHr6UAfeVFeQfDT4x2OtW8dp4iZLO/AAEvRJOP5163BNFcRLLBIkkbDIZDkH8aAJKKKKACiikJCjJIA9TQAtFZ11rFlaqTLKMexFY9x450aHlpxt7EkCgDqaKyNP8SaVfnFveRlvQnmtcHIyOlABRSEhRkkAeppFdWOFZSfY0AOophljXq6jtyap3WrWVvGzNcxZHH3qAOD+Ommxat4Z8j5vOXLKF5/SvjK/0iW1vJt4JK5yeuPavsHx34utPLkXKuMYYCvnzxJdadN5zpHhie+OKAPNwhbHA7AduSOKvQJsjUbcHvUk6RvOJETH+NN2hQQg+8ck+lAD+1MYAkAjPU+3+eaVsdduSAcGkyePlPPrjigCWG1Yg7ECjr0xmrDWEgi8wDcRnoO1WdNuoQ6i5GQOueBivS/BdhpWtXCWvnRwKcD5+cmgDyJlZfvKRn1FMYgMBkZPSvpvxN8D47my8zTJ1kl2k7ccHjtXzh4p0W90O+MN9E0bxscZHX/OKAKDxbmDA87gcE8VLxj3qvDPvK7htz69D9KlDKwDA8djnrQBIJAQVZiep4Pf/ADig4AwMk+tNoHIoAU0HkAE5A5HtT1BQrvXcDyFz+tMbAY4OR60AVbhNyk9MKTtJ/XiipJHGWCg+ZtyOPrRQBzJRwoYqdvXOKfCCu5trcDaCOxqxboPLYBQykjB9akdWTaY+FGcjtQA2WPeMBF+Q8DPUf0pqKImaPBZCMH1/zipoifKDMR0z9KJEDDHAJPB98daAM912SYBzj1GP0p9vEZC3BxggHtmn4HnfPywA6E8np/k1cQbVA9OntQAkMSoAq/ie9dBp9llldFK4wcbcms2xVpHCjJAOcHke39a6y0UWqBTgbsYXPQc9aAHwQ4XbIgOec+ntVe4j8uQgLhT05rRYZ+7wcYB64pHUI5bZ844OOtAFWG2GD5mCT6HkVCYn8xkC7io/SrxBVyUUHd15/Kj5vMBKA8dQefp70AZwRznCnjg+1Hlk7QQMP09K0JmKRM3Tp26VSuTmTht3GTyDzQBNDaKVG8lTkgADoK6nQvEfiTQoFOi6pMkZbcY2YsD+BrmNPZmYoct0xnp9K34o0VW3ZLkAHPOaAPR9A+NGvwjGr2NvdKP4kGxv04rZuvjoVjPk6C4fOMvNx/KvLbBY0uVQseRj5RkfhVbX5Ht7kINgXse/0oA9DufjjrcxaO20m1gJOFcksf51y2ufE7xdqQdHvkt0P8ESbf8A9VcasjZZmVdx61GXDk5YN05Jz9KANSTWNXvFYT3s0oPBwcdaoGaZiS8jkn1NJBlufmVScMenGabIAW+TO3PfrQBc07ULmzuo5YZmVge54r2Lwd4/dtkdxejKjnJ/zivEwm8HlcYyc1Zs41UqY3K7f4Qefz70AfVllq41QlrN9wXkgkZqwIbuSMtHvLHoK+ZrPV7+0jP2O9eHnIA5HNX7n4g+IUCRLfOEjHYY57UAes+KLy7skkW6uDG3UAnGO39K8a8SeIp5LmSNbpgQMHa36/SqF1qt7qExa/ummdudmc89axLgK4cAYUjjjOKAMnWL68ml+adyhYjkkf5//XWcJJCrKz8dw3Jpb3aZcKSSOvNOVMINyhh97OMde2aAInbdtKrwgAPFLDs8zDYCn+9z/n61FyegzSKwbO05wcGgDc13QbnQtTFtqIVNyJNC6/NHPEwyro38Skd/z5yKz50QKxQdSAPT8Pyr6S8MeG9P+KfwT0iC6lSPVNMR7WC6A/1LJwqt6qU8vI/Edq+br2A6feS2ztHJNA7IzRSh4yQSCVYcEe4NAFMxO74jB3HhuccVZ0q4uLO4WSKbaqkc9DUTzSeZu+Xd069PpVa5uJSEJA5GACPm/wA9KAPpT4cfEqa3hto7+XzYGwuSc+3T8a9K8beA9H8cacss0YjuHUMky/1r5f8AhPGuqanFbMVEmQV3nr/k19j6Epi06KB2UvGNp20AfG/xH+GV94MuldkaS3bpIoyD9MdK4HzVZlUq27PIx0r9Btc0iz1uwez1CJZIm9eoPqK+d/iF8C9QLeZ4eVJgzdF4KigDwPzQGCsMMTjr/n0qaJfMfauTzgkDpXvfhj9nR3tA+tXqwysudqruIJ7Gunl+FWmeGNEOY1u2z/rMYK0AfMwZreTy5Pujpxn8aFcFGcKuMY2qADj1NejeKvBsMrmeyfag5YYxmvNdRjk09njPOSBwevt+tAEC4fBXDdwRzRSeYC27hgCdxJooAyEIZQ44z6jmkXdubg7eMZ4+uKceBQpYDk884+lAAaWnONvynGQM8c5pWTa4Xadw6gnvQBCFCjCgYGSB71KrZA2qC3Y4/pSMMHFSWykzgA4I7jmgDc0y2SKIMBhmHPOcVvQxkFSRmQ8E1m2kB2RLjbuGc/zrp9NjRIoxIuFB4OOcetAEDWzBV2rlh1Pr09fxqF43YlsEgknPTPfNb7z2+0KV+UkZ4xiofILKGi3HIGc/rQBlpayMAQUIPPehbfkqzbW9MZyPWtGK2MavlSqjJJPc06KBpAWAHGRnNAGDOoMWxl2qBg4HSqGIzlgDsUjqeTWrcpidgcY7jrms+7UIqqseAON1AC2iNuLMmOeCf14ranuDa2oZiCeh9/8AJxVCEbmGT1wMk8fWl10HyY0Tjbg568UAWLXUfMeM/Kp3AnIOPpVzXSC6uW5x19vWubsx+8A3Hpn8j/n860rxmFsSQWIGDk9f8evWgCkjB7oEPuz7Yx7VPGihUCg4XoSKzcknGCSx61dG9JIgzHaSRyfyz70ATRqyg723Enj2qRlK43DGRkUxORuwwz2NONAEtum7liMD+HP3j6UmwyAskZxnsc1ciiKomSQVycZ4zV+ztHlKkDeO4JIoAyW8wLtcMwGMr6/j9TRPFmRWUHDDJB6iuhm03yiN/TocHvUc9mrKdow2fwBz3oAxxDsnDLhUUVzuuXeGaODIBJ9ga2dWumhJiRsPjBGK5K6kMkgLZ3AYb60ANhBD+YcseTkj0GRzUskrOnTaqgcep+npREMwjL5AP3cfy9+aaY8AAqwdmxkjAoAiZi33iSfUmkXAYZGR6Uh6elAGKAO8+GHjjUvBmrWT+dKdF+0eZc2yNw6soVmx3IABA9QPervxs8Jr4Z8RNd6bGh0PVv8ASrSRPujOGZB7DPHsRXBxO3kxctuzwOOQOMV7R4EeP4h/DS/8FX0gl1fSlN1pkhb5mAzhOfQnb16MOPloA8LAzk88Cqt2pZAfL+buc9K1L4PbXM0ciyJMh2srZDIR1BH9KoSkmIkDjHcf0oAh0vU7rTLqOayJWVXBBBxj/PFfW3wg8aC7sIBfzEyGP5ia+Q2QOpkwB3wBjI/yK1dN8Q39go8id4uNoKn/ADzQB+g9vPHcQrLC4dG6EGpK8s+E/ieMfDVL+aV55IuCp7n6+9d/4a1ddb0uO8ERiLEgoT0oA1KbLGksbRyqrowwVYZBp1FAHyl8a4bywu79rdjCqTHAB4wK8RmvJp8u7fOMfNn9K96/aRnuf7amV7djCRjheCB0NfPsSqzgMSBgk0AP82WRCo7fMT3opQgMqqpJJHBz+v5UUAQhSxY7s4GefTpU5iVH8uTgHo+cYp9tGNnJLHnKr2//AF4qaKPYSVJwxzjpigCssfKgbiOo7HIPIHp1/Sn7Du2SZB/hfjJ6VIEJQhDuPIbcx/XHWp4ovKhQEYyMgE0AUfJfGwp1Pyn0/KrKxgElgAd2cgnn0q8YUaENGSzDg7R3qCaLy5AMtgcjnqPegDoNHO+MAltuR8x4rfciGDIBwO2ayPDqD7GwlCkA5yT0rWn2yW5wRgc5HOaAK5lErlY0wW4LHritO1d1dEGdnp2xWNbjzJgiAt8w+v8AnmuijgVIwGG5s5yKALE4MiH7o3DHA6VnO0lrFIQ3I7Y9uv6VctneZJM7VAPTvx/+usuaTy2US7gTxk9qAMDUHZm3HjOeQf0xUabZUADFCgye/wCNS6g4Kqu3AJyPb/OapqrMdqgkn0oA1NP+eSNFILK2Bjvina+pedf7442j/P0q1oNtvuAyxhWA44HtxmoNZty15hzkn5iRQBn6bG2SdpwfQZ+uKtzttDluMewH6VatV+yWpdU3HGADVSbLq2ScnOcd6AM2OFnwBxnpk9asRBY2UrkhuDuIxxzmhSIYpFEgz2x1qFFLNgFSCeMev0oAuqCZWY5wOMGriqhZC5BJGMA+3FZtlExc5POcbfU1qyptliWJz1OB1280AW4N7sECADoOK2o3EEGFOH6cDGen5c1Xs0jt4mkmyzY6dKqTTM7kgsF7DNAGvb3jGM9GPTOelQSOQrOeTyazkl2upJwMjJPJ/OrepOEtXIZiSOSOOaAOO1Rw85cPu5Oe5rA2+ZL8u4gnkkVp3LNLPuUALkHJ6+lRxxrEmBzjPOOaALUEA+QMwVSOBnn2qvc2yhnkTICnGSeMgd6sxgyugRug7/w4qS7UyxgHaxOcY449KAOdxgnnNRyGTAKDnJGD0IqS4Rk3LtDMO1Z4d4nDEcEfKCc4HagDStp2Vcr3wTx/n1rb8Ja/eeGfEGn6tYNma2cOY+gZO6n2IJ/OuZFxlBvYox/2e3qKvCUeWEHBP3iefpQB6n8eNDtWvrDxloI3aNryeYzL0ScjLA46EjJI9Q9eRupLht2B0Pbj/wDXXTr4y1NfAz+E3+zyaW1wLhC6ZkjbrtQ5wATk9M8nnk1zTA5Uoc89WGDigCJ41ZyXO5f4QT3zg/0pYkgE0fnAshJJYnnj1qpIzg9Nu1iMrnFPY+YpMknA4455z1x6UAeh3HxKnsvDcWhaMv2eyUl2bGSx9cfnXrXwE8ZahqVuYVTfAv3iR1+lfO3hTR31nUfs8cbSH/ZXIr6Y0Caw+HugJFHGouZeWGPu+g/U0Ae4RksisepANOOccda5zwbrq6zYqzvmUruxntXR0AfMfxi8RXN5qssN7EphVtiggdPQV4r4j+zzzb7KIqg5x2avoT49+H/s16b6OLMc3OSDjNeH31qkYV9oJYfdIzj8aAOajRMKpO/H97t/nB/Kimz7hOpQZKjPJz146UUALaoRuywY5zwTU5HPfnrzTIF2qRknnH5cVcg+U5A3IzBcn/D8aAEitcIXb5V5YjHNNnfc2FbK+g4H5Vc2/umUZUH5eeOP8mqDkuwbgKBjAH5UASWp3ZaRmRiegPPepUjMjFXyXX+POQOelU4yQdytkZyD6VuaXG81zGrbPmOQF/zzQBs6VhbVYHA5OQv/ANam3UxIAO0BeSc54p+osIc4BHGWHQcdKr6DE99fJbnJDH3/AJ0AdDoWmNLGJeDuHGM1py2/kwbgSzdAPf6mujW2Om2KKF4AwO/PvXMzyKTuDMcnoeOfbmgCrbnMkuA3Xv0HtWbqaI8jMSQFPUD6ZroI9osXlZOf9odBXO3ameQNzjdkjPagDEv0/dq3Uj07ZqGyz5p5PAzgHrWjqNuzDKlArdAOlZSfu5PnLrx/D1oA6XTZDZOHLAyOB8o4NSX4hnBbG2THUmsYPzgFgccN6/So5JTGSDgdwcZ4/wD10AWLq5V3IL49BnpVKK6PmEPtwe/QChZPMkd0Vc44JwNvv71VBIfLfXkZ/GgCaSQIAIcAHk9+vakt1LEFRyDyS2BimMqqOMMD0bpg1Jbbw+zHHU+o96ANGCMPId4cjHRK0bVfNn28BVOwADJHvUNsDFCWwGJIPB7en1q5p8Ti7LkjBycD/GgC3qf7t1jJ6YJ+pql361c1VHE6lmUkgc9c1WjCOpO75uQB0/z3oAWNDI4RSq59RWjqMDXNliMZ2r6d/wDJqtYxFC2/O8DB9K6TTrYXNm4UEYXr/OgDySRCkhU9qYABnHfmr2uw/ZNRlRuOeB0/Cs2xkE8m1gQM+vrQBcgLAEK5xtOADnJ9hQ8shjw65XPVh3qZkymzATB6Dpzx9TUd0wZBhT8rFfYUAZmpxiQF9q444P8A9bisWRAZMgrhs9ORj+ldDMA0DcsODnArIlVQBxwONy8YH+FAFSaXaTtOW7OB1HSoFLFsKTk8daChBJwRjGc8U3nPtQBbjuXBIYKxAPtU3noBuLDPTaD71n0AkqMgA/yoAu4MkmHTKnkHfxj6U6S3jEZC/J6nrVSCUxPkdD1q9JIrJhtuzo2e3f8AGgDr/hvLdaZf/bbN8bCCHY9B/hVjx98Qb/VddjWBQNvyuy9q5nQbtzOtrbyYEoKemBW9daDFYXAmyXLHk44oA9B8JeKLjTra0RHbzWGXY/w8V9CeDtfj1ywyWH2iMDeB/OvkuC5aDTLl0y0w4SvZfgPrkMEQsrli0838fUA56UAenePLKwvvDlympBNirlGPUN7V8l6lBYLqEsMk48vecMCMDmvq74h6UdT8OXZWRlaKJmC9QeK+RLXw7LcXMtzeP5VujHGTjnP/ANagCvf+GHwZbNxPkZGD+JorWj0m5s1a80u6Eqx8lQev+f8AGigDhCCT8vTPfirSq0e2TduOOQQflH4VBbkpIu0kev0rQ7LswcYPJzxQAxnUvgrkY5z2H0qlIwkY7QFUZIAHJq3dEBQRnf8Aw4H9aqSxlMZ7jt60AJs2GPAGDyARgfSuq8NoiX3nSEYAIwRXN27NNOPMwwAPWt+wIEDYyc5z/n8qALN+VluJXIBDdgcjFbfgG2EV60jBXI9RWfBCj28bOuckgGui0CE2aPNt2jBwO9AHQ6tqJMbhB04wTxXHT3AaXegwcceg/D8an1zUWPy7DtPp6f5FZ1uPPGYhnPJ7UAXriZ/mhILIBn9Ov51nzlCCrHAzgcdf0qVom3OF5C9SKUpgMP4168jGKAKF1EMjYvJ7Af59qyHtTkszlh1J71uXuDBwvTHf9ay2U5OWJVuCCOgoAqiVfMXJAQMSBjjH+P8AjUMmN5+Yv70SLtPoe49KibOQRnryBQBO/wApYggbh/CfpkcUkbIrA4OR6nP5e9MyABjr3yKVMb+Vz6AUASB1Z2ZwFyCVPv2qxZYMxMRA44B4IpmNmNkR5HO0nI/zxU8Uaj5xksepOf60AaixK8CbCQMeuRWnYxkKHLg54PFU4d+0RZBJ6AAeg6VftiETy2ADjPHc0ATX0DvAJCVC9eOn6VR0+BonOSdvO09Af89a04lknjEaKcEhuR0NQ3MiREI2CckNQAK6l8JznkkdBXQeHZWLhAxI6EH0rlLfcshMf3TyQeOP1rc0x2Eiu+MoMcD1oAyPibo8VvqP2iAA9yT246V57aqRuYqFDcjH41674v2X9iNuN6DJP9a8uEGyfZtyM5OB1HrQBNAG+douADwM9fai8fMag4znPB6VKFClQFYKR15z7Z/+vTLokqSgDcYY9cYoAzpHSNMnGBwB71kOPNY7kXIb+I5JHrVm4n81yoPyr0H9arrKCwXGSVBGKAKphaJckA5BBYdqrMMAEYJIzWjONwACBmOcZHFVnjM8hMeRjg7u1AEAUlSRjA96bjIGcGpXjdcpwdvzHFR0AJGoEgdVUk4xx1qxL8xVuTu4B659eKrDC7VVePbtTsjpzxz0oA1NFmNneh+q4z9R2rs7WQ3sZmckJgkegrz61bEgBL89MfWvV9G04XPhma3ttzSMvUDn/P5UAcle+IUjdowFWLPAA6+9dV8IdWnu/Fltb2g+dnAAGfXpjFeXa9pk1nqQDnC56YPODXuH7KGhXs/iKfV57ZRaQIwRyO5GPzoA+m/EUrwaJeGOJ5nMZXavXkYzXw98RJtetLyZbkSxQByEQZwB/k1951xPxI0fRr7TDHfWsJuJCArkcqPWgD5B8JX9zZWomMrAHnaTw4orP+Kkq6TrEum2IyiZGQDRQAy1Cjcdv3mwee3vVqRmVeASMdRyfyqOJTvGchlUjPUHn/PFWPpQBHjzE5HTjDden6VFKm4Lu52/dzxu9vrVg5AGOTUW1mjYycN6ZwBj6UAVYh5c3zNs56jp9K2bOUDIYlQcYyeB+dYt3dxRkr8pKgYwc4PtVW21N2O05A4wQR0xQB2dtfLE6/Odp9cj8RXY6C4v4xGuG3/xdM15vY7rgr5fJ43Dqfyr1z4e2H+kxBgqbRyemKAOf17Tp0mEXUA4Ygf1pllB5NuSxYpjB3D616xrGh2aozK2ZTyx4xXCanbv5ckKRgE8KCegoAxIZDMf3YwcfOcfy/WiOJZYjvU5yfmxgnmrMNjJAjSSEBiOSTTVGFAwB7CgCjPZP5a4P3uD/tewrLubZg7MuAvcdMVt3lzlwB0DZ24xj/PH5VmtJtVmKsAPpzQBkPAhY5BU9DjjPsagktxz5fK55XP+fWtaO3DyMWcNg844OfenNagkBMcnJJ4P4UAZf2dCn3AGPPXpSWtqyvl8cdD/AFrbNugjUNGAD3x1qrJEyCTDYTjryaAI44g+VXO7PX+HFWY7NQwLMxA5OBSQgRxLucjJJAHftTrQny8EHIODk9KALsEG7G7Krxjtx/n+dXIYvLdzzg+p61UiuCoUNyF6cc1eikDruXIzxzQBbtQYV813ZQDwOmfSs2/aMyuy/wCs3fQjvV9Asrxq+FXHG2pY9PkbKx7STyeaAMGIN5hVW2MeOePwro9DizJtKll4AH09aii0t1mYFCMk8jqa29Fg8syMMBEHtye3NAGdfRqzS27fKx7HvXn95C8F/Kh3YA+UHgflXZ6/I0Vz5kb85H/6q4zWLhhNu/i9T3/zn9KAK7PtZgQqf3S3f1rOv7nCny9xUccnP40+4vEZNr4DDqcdPaqzItwoO47fQdjQBnU0khwP4e5P6CldDnDD5fQjrR0yeT7UALVWXdHM7rgtt6e3r+lWqUAk4HWgCgEaYhwQHPPXGMcVCsaFHBXDLzk/XpWmYs7mXhj3B9vSoDbLg4JLEg5bmgCjhiM8Yop7qqllLZI6YHf3qLGJCCwOckYGM0ALz/CcHsa9R+CuqudYjhvFfyWx8pFeZRSGNsgAjuCK9K+F8lq+p2/mOQdwbrQB23jjwcJJ5L+eLy4Nx2kjAOawPCvjy88K3P2TTpcRMxDKtdD8c/FsmqXljptmWitLZMMOhY4xmvIYgr3bFA7SjnPXBoA97k+LupwW++B97nruAYD86xtP+J194n1Bk1TaiqwRFUAA1zPh/wANXWt6RNcWsTu0fLqB0rNfRJ9NdpF4bPUdRQBe+NPw3uZ44dUskDiddxxzg0Vmr4q1u1vY4555JLeIfLG/Ixnj9KKAOeUbVAHQUpwFySPf2qDzFhjXdk56YOeP8ms27vHaQqQdnYDsf/1UAaUl0ijCjec/TFZdzethQGyMYI+nqPrVZ52O4KMdFAyd1RqhkXOGZu5zk96AIyJLh9zE5AyRnFS28LRPGGyoHAOfSpI0VMHK7/l+VucGprS2zJ8xyxOMn60AdFoMqwESuw4zxj/Oa7TTPErEhI1AUHgqMHgV59BE0GQWUp1JPB/wra0ghpNn3WHII6mgD1nTPEIvZVSUscDB78+taDpFsaRSHx1BJ7mvN4roQ/Kr/PxhcDr/ADroNF1eQTrG+RnBwenrQBJqSyOSSHDE/dA6iqADGDnp2Cnoff8AWtfUrt7lZMLgN0GM1hqMDGSfc0AZ12PnbAIbvls1mmTcG81CR9AMH/OBWpdjzCxIwOmDwTVC6H7piFxjv65oAICPMwhXb0wF9PetuGJI412qA2OeOntmsvSY43XkNn6da0LqZoiAu3kfjQBFebSwJYnsAOgNUgUUseB3JJqZ3dwTn+HHrx/+us8RMZmCHDDPJz/nuKAIpn3zMwJx0FXYW3RIctkgfp1qiQVzlSFzg5GP/wBVaFqjMqqqrluTtPGf8igCWJSzovByea07eLMir3Ocew71VjhaNwW+Zh0X29f1rYsOj+vFACYXc0cYMcm7AwTkir9kNk4YnBPLc8dKjdgoBYqB65q3byQS23zOgxjIGcmgDSnuYJWIQgnIBbHX6VS1J2RWhQSIjjJJ4JqjLNscyFguDwRT726/0UySsC4OOfpQBieJTGtmqry+3ksefT8a4bUipRdz4PTr2roPEN2HXO1mIOcjpXE3E7ZeNhzjA5/z2oAjjhd2zJkZ9eT/AJ6UgkeHcBkHnPHGfb070sLhnVduACMd+/f+WanuU/dEIAqj5jigDOkkAkG/OWPXHGaagO87gox0AB/n+dV7zdjkfiOmOw/rTrOQbQmTkdsUAXVVW/jCn3HFGOCFwfUg9R1/pSRxl+EBJFXIkXediKQMYYnJ+v8An0oAZLCvlbhjPUY9PT3+tVWR3xt3EZxnHUelawI/Km4wxO0cdMfrQBiyQKwYADnnPp/nmqphCgKxweTu6Adq15PK2kgEnkjAwAKgC5JwOcUAUFheVT8qqRznHX6Y7Vd0S4nsNTi8ncX3AfKfoageOWNtwYv3wRzzXQeA9MludVieVf3O4MSRnB70AdX4vsbn+z4NRnjbMo43Dr+Ncz5SwGN1VvMflh0/l35r1j4pa/pf2K00vT0BMUaiR27H2FeSahcKpWQZIUAgZxzQB7T8BfEkdvLqllcREp9mZyccDAzg/XkVh6BqdlrLXXnn5/OZdg4I9MVufAGxtf7J8Qa1fpstvsxhLOOOc5NeZadZyWmt3FzZqxtXcsCOeT/kUAb2teHZJJm8pd65znbnP/16K7nwZqP2i8RZLUztjOAOtFAHzfGzNz8pU9CDTJ48/OCAR1J9Kci44X5VDZwBjPFSEEuNvC+hNAGe0LDjG446Acjp/jUhTYoLyDcuQAvH61cPpyM+lRy7zuUJlSCOuKAK8KiSbIzxhuefwzmtayYDI25f+nFU7dDEgDksP88VdslByd3PIwPSgCyyBlYH+LqRxWrZoYUJzhjyCM1nwqu4KQxHscmtFAABuGG9c9f84oAu20Q8tpH6YPHtVi2uQH3ISpPHLZ/SorHBU4JyDzzUbQO8xO04J6nAoA6kSnyxzuc87v8AD8qrhX3k7/lznGKSxzJEoHLDNTEZJ49+O1AGdflgwAcqv3iG5FZzxs8wDAEDnBPYntWjeQEtJnJQjOTUa2zMBhOVOB2IoALSTynA28bQP8mnTs7OPMxux09Kl0a2YtICd0g5y35U+SDzJZDnnAI5/wA+lAGY1yRLtPC9C2ePb+VKHUsHXO05yc9PfH4UtzbASFnLKV7j0HpUEUO6FWjcqT1z3oAmMccoyVJ571q21qITx8xA446Vn20ADbFOATnk10VgCAx3DHAPrQBVCsxYgE+tWJ5xY2wL9epGc4qxEroGMrA854rn9Xmea6+UrsU4BP8An1oAqzXpu5JCxZEzkEcCpY5miYbXIwc4zVCVlXcqKA3IwOcjrmoTIS6sSMge9AHSwajtVVcLgc8jODVO6uTKwAY4PUE9axjM55JO719PpUkTswEYGWY53E5x70AJeF2G8bWQZ24PWuW8vzJnMiE8/Ke3FdPcIVhbdkjowPUnFc9NHh1ZWbg/dXoTQBFHAySKdq4zknP6VLcHET5zjHb1p/HTAI704ooQKefUHmgDAvYxsJbcCD06/wD6qgtkbzhgkAYzj6ZrUurcEMScoTx+NUo4CsgJbpz+JoAvW7sDtUfKTzgZzWlbRG4lSKLJJJXAH8qzoxIigqGx97OOn+PFb2kPsJkdcNyAOCRxQBHFpkjXTRxhS2MnAGahu7fyHKyMDkYxmtNWKSPIhxI3U/8A1qzbr5pCxfcW5OOooAqGQmRFUrk5IY8jHoKjhjUMZHUgjt7/AEqaNCpOcleo3HJFJKA6ugGWK/8A6uaAF022ivLqTzQQueMHjr7V19ndRWaGKEBGXgP3965/woiLeMLhTubPOAMV6EPDccmjxzRpmVzkkDjH0oA4DVZXkuPMJPzZxn/CtHwX4Ru/GWqCwtkIUHLOegFUvENvHbuxR8kDGAenFb3wZ8azaVfz2tuigkbfMBJ/l0oA908W6PY+F/h3Z+GbZlj+1MI2cfxHuT+lcnf+HrbSdPhgUqytxnOf1q/48vbjxJZ2MrKU8ojDYx+NdT4I0TT9Sgjlu5hcvH0Qtn/IoAw7W0bw5oEd7ZwKszJ8shGccUV6Nqkuiy6VPbNcWvlRLkqjglfwzRQB8GIcgjJJ6Eg/pxT+MdK5mDUxv3IV68e1Xk1RnbZjbk8HFAGvSw5eRQF7jGRwaz4Z2kKKzdT1xyD6Vowgb1HXpgHv7UATRKwl2HcPYnjH9avKCBjgew7VAEUkja3XjIPB9sduKsAdAMn0oAt2kYOGIBIPrnip5ZGDL5YU7uQM9arwuiQhj94dg2CeaRC08ihk/d8kDoMUAbFjt68b+hHWrjE+ZhV+X1pulWpkiZ8Hk4GOprWj01pVByS+SDj/AD1NAFrQLZpPLSLaC3y56CjVFe31F4HZZdnBkj5X8PWtJLP7NbqBgYwMD6VS1BIw4MYI3Z5NAGc0hEZJT5sE4B/PmooZJWKnC7XzjjoadKx+aNgFDfdx1aprNTJGAgOR2JzigCSyWYwyS4ZCvP4d/pVizgVlZpBuJ6H25q1qTx6dZJCyMXlHXpiqGiv50jtKyooB5oAwdVbbJIoZSu7BPU/h+VR6ewCDdlgpzjHH0qbU3b7TL5aho+Rz19KqxTsyMH5LZC44IoA1TKskynazEcqo9a2bAjBxjcDzx1FYNs4VdxyrHgk8gf8A160dPkUMoZME/wAHTB9cf560AamqbEtt/ADc8cjrXJXUcc9wXO7kcAmuou9hgIbkdB3ya44M32tgRvAPTHT6UAWFQbt7Bd/qKozq0Tlc5B555z1rQdJBEWIKE98ZFUr1gxTAIOMnIoAqkEMu3bt5z61IEYxl8fKDip1tyyKx/iwMAdPf/PrUsEIUvx7K2efegCqXP2byyOpzknp9P1rIljImKqWY88Ec1szJtITO449e/FX9K8L6pq/FhaOxP8Srz/k0ActHGWYhR8wyTx/SpJYCIQWzuzjANdZqnhDWdGcJfWUqM2Ooz271Vm8Pan5SsLNmZvuZXkUAcdefdA4PfntiqqwOygqAQRkc12994O1S30t7me0mGRzuByPWubkheFysiOrA5IOeKAKQtmRwwIOOnuf6Vo26qkbSuM9gG55qJVleTZFG0jEcBR710+h+BfEWtSKLbTZ/LPRypxigDEt7gELG6g/w+2MUy4iYb3YA57g9K9Q0L4I69dahs1Apa2o5LscnHoMVT+KXhBPCksUKTGYBA4bpzQB5l26Uh4GcgDvmngvPIMKzOxwAF5P4V6J4P+Fes+IVSZk8mBjzI/A/+vQBmfD7SI7zUFaX/VgbiTXbeL/E0NjpP9j6NGqJyHmOOT6CvUPB3wx0vw/YmO5Y3UzD52PC15h8SLDS766e20iDbBC20yqeG/z/AFoA8K1mK5nvDErmQkf3eea9L+AngO/nu3uHh2wk5+foRXW/D7wRp1uP7Q1OLz0P3F64r2TwYFPneTbJBAoCrtXFAHLfFY2mh+DLe0cok0j4EijnI/z+lfO+r65q2jQGWzuWRXUgYJ469a+hfjzol1rejwJaLuaEF+OvvXg914K1zW4LO3is5CcgsAvFAHmemeMNYXU3hlnY+b975veivavDv7Puq3GrCXUAttCDk7j247UUAfLNSxyyBxtYknA55zS2ltPeXMdvaQyTzyMFSONSzMT0AA61pw+Gtbl1qfSYtIvZNSt9wmtVhYvHtGW3AcjA5oAl02diyqwBBz8uc4/KuojJUJIpwWGRXE6TBdXt3FbWcMk8sr7EiiTLOx6AAV3nha1vNWnFnZ2U91dBWLQxR7iNvU+wAzQBbiYPz/EQMj0HapQoKkkgY6cd6rrCo2vGTjqBng9f8anUE4HAP1oAVXADLgHPfHStnQrF55DnAThgOuaytvkyL5q54ziuw8Ix/aLiEBSdxyRn6UAdT4f0WS4YFVyFXgHitFrFUu1RvkKtg45z6V0kMQ0u3jRVCSEeuMnFU43FxcurMwbOeBn8KAKmpxL9nVEG0HqwPfFcrqLBYVCliTyR6/54rsdViEW0E5PY1zOoQxlmAHbPHagDmJwSxdwGXpuT+ddR4PtDeXSLIBknnjGKxoo8ybBkZPT0rvNJtBp+kyTRJiVlJ60Acb40x/bLwqzSeXkDBzVHSdwWUn+FSV9jT9WmLXUkrbVkyTg+/eq1gjCORzIGLHnnGB6UAZ1wnmTS4dsHK8nI9iKbAp3lXwSAAg4J9M1eRUYOu0o54GTx6j+VQNEVbkYySM54NABk44YnbyMdq0LdgyZy2Sc/Mf5e1V4cBR5g4VsdfX/PB96t2sbSPtjC7AOMHP40AWVVZIPL+6x4znr+FZraUY5Q+CCflOB15rp7aBDIrsgIHAx/Knyxhp1RQAehxwPy+lAHLahbyhgpViAOxOaybxWGJFOMYz/T+ddhqkJFwAoyTxwMe9Y8mmT3KtDCnzcYyvOKAMpZ1dQq5aQjG1c9a6Xw54F1zVAZUtnWNuQ2M5rvfh18K8hLzWk2gcqp6mva7aCK2gSGBAkaDAAGKAPGvAfwiMF4bzxHhlBysIOd319K9is7G1skCWlvFCoGMRoBxViigCC5tLe6AFzDHLjpvXOKclvChBjijUjphQKlooAbJGki7ZEV19GGa5q+8CeHL68e6uNMiaV/vY4Brp6KAOcsfBHhyxmSW30m2EidGYFv510SKqKFRQqjgADAFLRQAVzfiPwbpXiG587UkkY4wQrYzXSUUAcjpvw68M6dcCaDTkLAYw5yK61FVFCooVRwABgClooAralafbrKS3MrxCQYLL1x6VgQ+BtHjs3txHIUclmO7kn8q6iigDL0rQbDTbcwQRFkIx+8O7itKKNIkCRqqqOgAxTqKAGvGj/fRW7cjNEcaRqFjVUUdlGBTqKACiiigD87fgNr83h74naLcRXEdtDNOkNxI+MCJmG7JPQYr2/wH4ugs/j18QoTqlnHod6JpjM0qiOV1UBcMeD/ABdDXy3aKgj3j7/OSTgVdjDM2FOMjk5xxQB2fwqNro0+s67ctEr6bps0lqkjAGSdh5aYz3Bfd9F9q7/9lbxKdJ1rVNPu76K106a1eRjMVUM6j5fmPfk15AsB8rcE3I3zEjkH3qJYtjqULcH+9igDp9NcuducKecNxitnEccDMigP93k8g1gaWrP5ZAYnpnB5J+tdEA6wICm5x0HXHvQBS3My7S2R6E16T8HtNNz4gg85iqL1JrjLKxaaZFRSFPRSOM/h1r1HwZbvbzxxQqAxxvK+tAGzrc0jeIp0Q7kQ4XHOPaqUUnkXPmqvz5ywPc1r6nGqSuIU/e8hm6ZrnDIDP5eSAOeM5z/hQB0l6WvYS4QZxyynj/Peucv4PNVuPLYKf88109rGx0wEMAAO3cY/+tWdcJEy7mIBxnI5+lAHK6Zaut2GYlmJ6da7G7lWHR1jDDzDwVAyTWHYWzG92YO0njnANX9dIj3Rk7iq4z9aAOI1SRHd38v5QcehAqtDhrVljHPI54zV27QbmD4O7nAHr61Xgi3wny8xqeT82O9AEUdqWO0j5s/KwOPpUkkT22EJZjn1AB/OrPzIiyICAO4Izmq9wV2LuAGCcH14PWgCCSfKsGQlDx0xg+laOmhfJDISB0APAJ/zmsmSUy43jjoB0Ga3bGENCqoD94kAHv60AadnB543oTlSPu81GZCbwYQcNg9P85rSt1eKyk3qAo/iA7Uzwnod5r2qtHbxkRIclz0UfWgCRNMuby4iS0jWSVh6fzr1nwT4Rg0W38+5jV72QZO4A+X7CtfQdCtdJiHlorT4wZMfoK1qACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsq/wBfsLC4MNzIysOpxwK1a8O+PAvra6D24byHTczAdKAPXjr+kiF5TqFsFQFjlwDjGehor4Q8Ua9PCssf2l1IUjGTz/nNFAHmlvKIm5Pynrx0qf7XH6N+VUaKAOgTX0SLYLdnz1y+P6VVfWWLErCqj03E1S0+NZblVkGR6fiK7SzsrVYMi1gJCA5aME5yPUUAQeHfEtp5kVvfxNEOAHQbgT7ivSo7aNF3uwYdvSudsHEMJMUUCnYDxCnt7VHNqt41x5Rm+QkDG1fb2oA7rTTn96mPl4DD1710WmTy2p3o4Dv83X6V57p+oXKwELJgBv7o/wAK1bDU7wq4M3Axj5R/hQB6vp8zSwSO8i7sYPfOaxJGjW+2vgSnjHA5rF03Urv7O/73GVLcKByDx2qEX1xLqcbSSBiBn7o7n6UAeiQ6jCLAwKoB7k9hVaLYYsIAUPrXP3VxIs7AMAOOAB6VYku5orWMxuFJxn5R6UAXVR7bUo1Eg+UnPH3qu6/ZJIgkEi/MueB3ri7y+uTckmU5HI4HpUunX1w9oN8pbPqB6CgCleJHGh2kl/QDmq2mpl/3rHk9GGM1XmnkN5gtwWHarmluWeJmOTz2oAk1DYCQU2J09BWdLM3Hy85BU9BVnW5X8/GRg8YwPasmV2aRSTkscH8jQBchkZ5sSkDsBjg57fyrodDEkkgES5JO3aB+dclExMak9SK9R+Fscb3025EbYvy5UcUAdb4d8C3FzGk+ouYI3/5Zg/MRXf6RZWunRG10+ARwL1YHqf61kNfXL3FvE0p8tjgqABmunAwMDgUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADZZEijaSRgqKMkntXy9+0d8U3kA0XRwvlDPmOR8xP8ASvVfjRqd7ZaTMlrcPEpTouPeviXxFdz3V+xuJWkJAOW9aAMe8nnmDtIRICvDZ5oom/1L/wC6aKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium swallow in a 62-year-old man demonstrates a dilated barium-filled esophagus with a region of persistent narrowing (arrow) at the GE junction, producing the so-called birds beak appearance. Achalasia was confirmed with manometry and the patient underwent successful dilation of the esophagus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_35_20016=[""].join("\n");
var outline_f19_35_20016=null;
var title_f19_35_20017="Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Patient drug information";
var content_f19_35_20017=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34488?source=see_link\">",
"     see \"Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/13/17624?source=see_link\">",
"     see \"Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adacel&reg;;",
"     </li>",
"     <li>",
"      Boostrix&reg;;",
"     </li>",
"     <li>",
"      Daptacel&reg;;",
"     </li>",
"     <li>",
"      Infanrix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F161262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adacel&reg;;",
"     </li>",
"     <li>",
"      Boostrix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10030557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_dtap.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS) - DTaP",
"       </a>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2706008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_td-tdap.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS) - Tdap",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11721 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-9318902EC1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_35_20017=[""].join("\n");
var outline_f19_35_20017=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161261\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161262\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030557\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/43/34488?source=related_link\">",
"      Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/13/17624?source=related_link\">",
"      Diphtheria, tetanus toxoids, and acellular pertussis vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_35_20018="Patient information: Elbow fracture in children (The Basics)";
var content_f19_35_20018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17126\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/0/44047\">",
"         Elbow joint",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?10/51/11058\">",
"         Patient information: Cast and splint care (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/34/30243\">",
"         Patient information: Fractures (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?25/21/25937\">",
"         Patient information: Cast and splint care (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Elbow fracture in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/elbow-fracture-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H29378046\">",
"      <span class=\"h1\">",
"       What is an elbow fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An elbow fracture is a break in one of the bones near the elbow. A &ldquo;fracture&rdquo; is another word for a broken bone. The elbow is a joint made up of three bones (",
"      <a class=\"graphic graphic_figure graphicRef58954 \" href=\"UTD.htm?43/0/44047\">",
"       figure 1",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The humerus &ndash; The humerus is the bone that runs from the shoulder to the elbow.",
"       </li>",
"       <li>",
"        The radius &ndash; The radius is one of the bones in the forearm, the part of the arm between the elbow and the wrist. It is on the thumb side of the forearm when the palm is facing up.",
"       </li>",
"       <li>",
"        Ulna &ndash; The ulna is the other bone in the forearm. It is on the &ldquo;pinky side&rdquo; of the forearm when the palm is facing up.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In children, most elbow fractures happen:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Above the elbow in the humerus",
"       </li>",
"       <li>",
"        At the knob of the elbow at the end of the humerus",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29378061\">",
"      <span class=\"h1\">",
"       What causes elbow fractures in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Adults usually get elbow fractures when they fall on an outstretched hand. But children usually get elbow fractures from different types of injuries. In children 3 years old or younger, most elbow fractures happen because of a fall from a bed or couch. In older children, most elbow fractures happen because of a fall off the monkey bars or a playground swing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29378076\">",
"      <span class=\"h1\">",
"       What are the symptoms of an elbow fracture?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include pain, swelling, and tenderness around the elbow. Most children who have a broken elbow are also unable to move the injured elbow. Plus, many children who have broken a bone remember feeling a pop, crack, or snap when the injury happened.",
"     </p>",
"     <p>",
"      If you think your child has broken an elbow, see a doctor or nurse right away.",
"     </p>",
"     <p>",
"      Call 9-1-1 for an ambulance if your child:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Has severe pain",
"       </li>",
"       <li>",
"        Has a very crooked looking arm",
"       </li>",
"       <li>",
"        Has any bones sticking out through the skin",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29378091\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your child&rsquo;s doctor or nurse will ask about his or her symptoms, do an exam, and take an X-ray. During the exam, the doctor or nurse will look at and feel the injured elbow and check the pulse in the wrist. He or will also ask your child to do some simple finger movements, such as pinching something, spreading the fingers, or giving a &ldquo;thumbs up.&rdquo; This can show if the fracture caused any nerve damage.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29378106\">",
"      <span class=\"h1\">",
"       When should I call my child&rsquo;s doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should call the doctor or nurse if any these symptoms occur after your child&rsquo;s fracture has been treated:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The elbow gets very swollen",
"       </li>",
"       <li>",
"        Purple spots appear near the elbow",
"       </li>",
"       <li>",
"        Pain in the forearm gets worse",
"       </li>",
"       <li>",
"        Pain gets worse when the child stretches out his or her fingers",
"       </li>",
"       <li>",
"        The hand gets cold and pale",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These symptoms could mean the arm muscles and nerves have been damaged. If this happens, your child will need to have his or her cast taken off (if your child was wearing a cast). The doctor will then follow your child&rsquo;s symptoms and decide whether he or she needs more treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29378121\">",
"      <span class=\"h1\">",
"       How is elbow fracture treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment depends on the type of fracture a child has and how serious it is.",
"     </p>",
"     <p>",
"      If your child breaks an elbow, he or she will likely get medicine to help with pain. This might include",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"       ibuprofen",
"      </a>",
"      (sample brand names: Advil&reg;, Motrin&reg;) or",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?14/33/14870?source=see_link\">",
"       morphine",
"      </a>",
"      . If your child gets morphine, it will need to go into his or her vein through a small tube called an &ldquo;IV.&rdquo;",
"     </p>",
"     <p>",
"      If the ends of the broken bones are not far apart, the doctor will probably give your child a splint or cast, and a large bandage that hangs from the back of the neck and supports the arm (a &ldquo;sling&rdquo;). This will keep the arm from moving while the bone heals.",
"     </p>",
"     <p>",
"      If the ends of the broken bones are far apart, the doctor will need to move them back into place. Often, the doctor will need to do surgery to move the bones, but not always. Once the bones are in place, the doctor might use pins, screws, or wires to keep them from moving.",
"     </p>",
"     <p>",
"      After your child gets treated by a regular doctor or in the emergency room, he or she will also need to see a doctor who specializes in treating bones, called an orthopedic surgeon. The orthopedic surgeon will decide how long your child should wear a splint or cast. He or she will also take X-rays to make sure the bones are lined up correctly and healing well.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29378136\">",
"      <span class=\"h1\">",
"       Can elbow fractures be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Make sure your child only plays in playgrounds where there is at least 6 to 12 inches of soft surface (such as mulch, sand, or shredded rubber material) under the equipment. Also, make sure your child wears elbow guards when he or she is doing sports such as skateboarding.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25148341\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=see_link\">",
"       Patient information: Cast and splint care (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=see_link\">",
"       Patient information: Fractures (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"       Patient information: Cast and splint care (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?19/35/20018?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17126 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-1201EFFE29-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_35_20018=[""].join("\n");
var outline_f19_35_20018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29378046\">",
"      What is an elbow fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29378061\">",
"      What causes elbow fractures in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29378076\">",
"      What are the symptoms of an elbow fracture?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29378091\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29378106\">",
"      When should I call my child&rsquo;s doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29378121\">",
"      How is elbow fracture treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29378136\">",
"      Can elbow fractures be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25148341\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17126\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/0/44047\">",
"      Elbow joint",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/34/30243?source=related_link\">",
"      Patient information: Fractures (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_35_20019="Cantharidin, podophyllin resin, and salicylic acid: Drug information";
var content_f19_35_20019=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cantharidin, podophyllin resin, and salicylic acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/29/18899?source=see_link\">",
"    see \"Cantharidin, podophyllin resin, and salicylic acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13314942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Canthacur-PS&reg;;",
"     </li>",
"     <li>",
"      Cantharone&reg; Plus",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13314943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Keratolytic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13314955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note: Applied by physician only.",
"     </b>",
"     Treatment should be initiated on 1-2 lesions until sensitivity to treatment is established. Refer to Administration for detailed application information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Warts (plantar, heavily keratinized):",
"     </b>",
"     Topical: Using a wooden applicator stick, apply the product sparingly (single layer only) to the wart and a 1-3 mm margin around the wart. Re-evaluate in 1-2 weeks; retreat in similar fashion if wart tissue remains. For large mosaic warts, treat a portion of the wart at a time; &ge;3 treatments may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Molluscum contagiosum:",
"     </b>",
"     Topical (Canthacur-PS&reg;): Apply thin film to each lesion then re-evaluate in 1 week. Treat new lesions in similar fashion; resistant lesions should be retreated and covered with occlusive tape for 6-8 hours then remove tape.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13314954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F13314956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15794330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15794331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13314999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Canthacur-PS&reg;: Cantharidin 1%, podophyllin 5%, and salicylic acid 30% in a film-forming vehicle (7.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cantharone&reg; Plus: Cantharidin 1%, podophyllin 2%, and salicylic acid 30% in a film-forming vehicle (7.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F13314983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13314980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake well prior to use.",
"     <b>",
"      For external use only; may be fatal if ingested.",
"     </b>",
"     Not for use in or near the eyes, on face or mucous membranes, birthmarks or moles, warts with hair growth, or anogenital area. Do not apply to inflamed or irritated skin. Avoid treating large areas with 1 application as this may increase systemic absorption and cause excessive discomfort. If contact with healthy skin, wipe off with acetone, alcohol, or tape remover, then wash area with warm soapy water and thoroughly rinse. If contact with mucous membranes or eyes, flush with water, remove precipitated film, then flush with water for additional 15 minutes.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Method A (no curettage): No cutting or prior treatment is required. Occasionally, nails must be trimmed to expose subungual warts to medication. Using a wooden applicator stick or cotton swab, apply to lesion(s). Allow to dry for a few minutes. Cover with a piece of nonporous plastic adhesive tape for at least 4 hours (up to 8-24 hours). Within 24 hours, a blister forms which is often painful and inflamed. Reevaluate in 1-2 weeks. During this period the patient may or may not do periodic soaks as preferred by physician. Remove necrotic tissue and treat as before if any viable wart tissue remains. Allow tissue to re-epithelialize before retreatment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Method B (with curettage): Proceed as in Method A except have patient return in 1 day for curettage. Local anesthesia may be necessary. Treatment with this method (next day curettage)  enhances identification of tissue planes, increases separability of wart tissue, and retreatment is rarely necessary. Reevaluate in 4 weeks. Usual healing time is within 1-3 weeks. Apply a mild antimicrobial agent until treated area heals.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Mild analgesics (eg, acetaminophen or aspirin with or without codeine) may be necessary. To minimize pain after application, bandage should be removed shortly after symptom onset and after allowing sufficient time for absorption, and (if needed) the area then soaked in cool water for 10-15 minutes. If persistent pain, puncture blister then apply antimicrobial and cover with sterile dressing (eg, BAND-AID&reg;).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F239668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For removal of warts especially plantar, mosaic, and periungual; recommended for resistant and heavily keratinized warts; useful where painless application is desired. Canthacur-PS&reg; is also indicated for removal of molluscum contagiosum.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13314947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Annular warts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local: Burning, extreme tenderness, pain, tingling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Chemical lymphangitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13314944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation; use in diabetics or individuals with impaired peripheral circulation; use near eyes or on face or mucous membranes; in anogenital, intertriginous or axilla areas",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canthacur-PS&reg;: Additional contraindication: Ethanol consumption for several hours after treatment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F239662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dermatologic: Strong vesicant that may cause blistering of normal skin or mucous membranes; reactions may be more severe in patients with fair complexion and/or blue eyes. Do not apply to irritated or inflamed skin. Residual pigmentation has been reported (rarely) with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Children: Avoid use in young children (&lt;12 years of age); pain management may be difficult in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate personnel: Should be applied only by a physician; not recommended for dispensing to patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use:",
"     <b>",
"      For external use only; may be fatal if ingested.",
"     </b>",
"     Not for use in the eyes, on face, or mucous membranes, birthmarks or moles, warts with hair growth, or anogenital area. Do not reapply to the same lesion &gt;1 time per week. Avoid treating large areas with 1 application as this may increase systemic absorption and cause excessive discomfort. Do not use in combination with other chemical wart therapies.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13315241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reports of podophyllin use in pregnant women have shown evidence of fetal abnormalities, fetal death, and stillbirth; use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13315242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13314982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treated areas for adequate healing; pain and tolerability of treatment",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13733184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Canthacur-PS (TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13314951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Salicylic acid is a keratolytic that produces desquamation of hyperkeratotic epithelium via dissolution of the intercellular cement which causes the cornified tissue to swell, soften, macerate, and desquamate. Podophyllin directly affects epithelial cell metabolism by arresting mitosis through binding to a protein subunit of spindle microtubules (tubulin). Cantharidin is a vesicant thought to cause wart exfoliation via its acantholytic actions.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17053 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-50E636C042-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_35_20019=[""].join("\n");
var outline_f19_35_20019=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314942\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314943\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314955\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314954\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314956\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15794330\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15794331\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314999\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314983\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314980\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239668\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314947\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314944\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239662\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13315241\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13315242\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314982\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13733184\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13314951\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17053\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17053|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/29/18899?source=related_link\">",
"      Cantharidin, podophyllin resin, and salicylic acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_35_20020="Renal allograft biopsy showing ATN light microscopy";
var content_f19_35_20020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F80709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F80709&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Renal allograft biopsy showing acute tubular necrosis by light microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Renal allograft biopsy showing acute tubular necrosis with sloughed and swollen epithelial cells (arrow) and, in the upper tubule, scalloping of the epithelial cells and an intratubular cast.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ann Crosson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_35_20020=[""].join("\n");
var outline_f19_35_20020=null;
var title_f19_35_20021="Acetaminophen (paracetamol): Patient drug information";
var content_f19_35_20021=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acetaminophen (paracetamol): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     see \"Acetaminophen (paracetamol): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     see \"Acetaminophen (paracetamol): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acephen&trade; [OTC];",
"     </li>",
"     <li>",
"      APAP 500 [OTC];",
"     </li>",
"     <li>",
"      Aspirin Free Anacin&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Cetafen&reg; Extra [OTC];",
"     </li>",
"     <li>",
"      Cetafen&reg; [OTC];",
"     </li>",
"     <li>",
"      Excedrin&reg; Tension Headache [OTC];",
"     </li>",
"     <li>",
"      Feverall&reg; [OTC];",
"     </li>",
"     <li>",
"      Infantaire [OTC];",
"     </li>",
"     <li>",
"      Little Fevers&trade; [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; Arthritis Pain [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; Infant's [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; Junior Rapid Tabs [OTC];",
"     </li>",
"     <li>",
"      Mapap&reg; [OTC];",
"     </li>",
"     <li>",
"      Non-Aspirin Pain Reliever [OTC];",
"     </li>",
"     <li>",
"      Nortemp Children's [OTC];",
"     </li>",
"     <li>",
"      Ofirmev&trade;;",
"     </li>",
"     <li>",
"      Pain &amp; Fever Children's [OTC];",
"     </li>",
"     <li>",
"      Pain Eze [OTC];",
"     </li>",
"     <li>",
"      Q-Pap Children's [OTC];",
"     </li>",
"     <li>",
"      Q-Pap Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Q-Pap Infant's [OTC];",
"     </li>",
"     <li>",
"      Q-Pap [OTC];",
"     </li>",
"     <li>",
"      RapiMed&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      RapiMed&reg; Junior [OTC];",
"     </li>",
"     <li>",
"      Silapap Children's [OTC];",
"     </li>",
"     <li>",
"      Silapap Infant's [OTC];",
"     </li>",
"     <li>",
"      Triaminic&trade; Children's Fever Reducer Pain Reliever [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; 8 Hour [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Arthritis Pain Extended Relief [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Children's Meltaways [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Infant's Concentrated [OTC] [DSC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Jr. Meltaways [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; [OTC];",
"     </li>",
"     <li>",
"      Valorin Extra [OTC];",
"     </li>",
"     <li>",
"      Valorin [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F129319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Abenol&reg;;",
"     </li>",
"     <li>",
"      Apo-Acetaminophen&reg;;",
"     </li>",
"     <li>",
"      Atasol&reg;;",
"     </li>",
"     <li>",
"      Novo-Gesic;",
"     </li>",
"     <li>",
"      Pediatrix;",
"     </li>",
"     <li>",
"      Tempra&reg;;",
"     </li>",
"     <li>",
"      Tylenol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691598",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain and fever.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701411",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acetaminophen or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703831",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad liver disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of acetaminophen. An overdose may cause problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694768",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more than what your doctor told you to take. Liver problems may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694830",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eat often to lower the chance of liver problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695322",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-acting products: Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696308",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle contents of capsule on soft food or liquid. Do not chew.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (elixir, suspension, solution, syrup) if you cannot swallow pills. Shake suspension well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705560",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Suppository:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696199",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use suppository rectally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699157",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not freeze suppositories.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12338 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-220.255.2.130-1001A7F1F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_35_20021=[""].join("\n");
var outline_f19_35_20021=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129318\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129319\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026564\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026563\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026568\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026569\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026571\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026566\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026567\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026572\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026573\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=related_link\">",
"      Acetaminophen (paracetamol): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=related_link\">",
"      Acetaminophen (paracetamol): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_35_20022="Acute aortic regurgitation in adults";
var content_f19_35_20022=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute aortic regurgitation in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/35/20022/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/35/20022/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/35/20022/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/35/20022/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/35/20022/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/35/20022/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/35/20022/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute onset of severe aortic regurgitation (AR, also called aortic insufficiency) is usually a medical emergency due to the inability of the left ventricle to quickly adapt to the rapid increase in end-diastolic volume caused by regurgitant blood. If not surgically corrected, acute severe AR commonly results in cardiogenic shock. In contrast, clinical symptoms are a relatively late feature of chronic AR, since the gradually dilating left ventricle and compensatory mechanisms dampen many of the hemodynamic abnormalities resulting from chronically increased diastolic volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20022/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to acute AR will be reviewed here. Chronic AR is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=see_link\">",
"     \"Course and management of chronic aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of acute AR with a native aortic valve are limited and include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endocarditis &mdash; Endocarditis results in valve destruction and leaflet perforation. In addition, aortic perivalvular abscess may rupture into the left ventricle, resulting in AR, or into the left atrium or right ventricular outflow tract, with a clinical presentation that mimics acute aortic regurgitation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=see_link&amp;anchor=H5#H5\">",
"       \"Complications and outcome of infective endocarditis\", section on 'Perivalvular abscesses'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aortic dissection &mdash; Aortic dissection can result in AR by four mechanisms: dilation of the sinuses with incomplete coaptation of the leaflets at the center of the valve; involvement of a valve commissure resulting in inadequate leaflet support; direct extension of the dissection into the base of a leaflet, resulting in a flail valve leaflet; and prolapse of the dissection flap across the aortic valve into the left ventricular outflow tract in diastole impeding leaflet closure. Patients with a bicuspid aortic valve are at higher risk of aortic dissection [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20022/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of aortic dissection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"       \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rupture of a congenitally fenestrated cusp &mdash; A congenital valve fenestration in the overlap segment of valve closure may rupture, resulting in acute severe regurgitation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20022/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Traumatic rupture of the valve leaflets &mdash; Traumatic rupture of the aortic valve can occur after deceleration injury or blunt trauma to the chest [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20022/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Iatrogenic &mdash; Iatrogenic causes include aortic balloon valvotomy or a failed surgical valve repair [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20022/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39411?source=see_link\">",
"       \"Percutaneous aortic valvotomy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The two most common causes of acute AR of a native aortic valve are endocarditis and aortic dissection. This was illustrated in a single center review of 268 adults referred for aortic valve replacement for isolated AR, 18 percent of whom had acute AR [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20022/abstract/8\">",
"     8",
"    </a>",
"    ]. All of the cases were due to active endocarditis (56 percent) or acute aortic dissection (44 percent).",
"   </p>",
"   <p>",
"    In addition, acute aortic regurgitation may develop with aortic valve prostheses. Acute mechanical valve regurgitation can be caused by valve thrombosis with incomplete leaflet closure or disk escape with older valve models. With bioprosthetic valves, AR may occur with valve rupture adjacent to areas of leaflet calcification or leaflet destruction due to endocarditis. Paravalvular AR is caused by prosthetic valve dehiscence which can occur as a complication of endocarditis or other cause of inadequate valve attachment such as the aortopathy associated with Marfans syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In chronic AR, the volume overload of the left ventricle is associated with a gradual increase in left ventricular size that maintains a normal forward cardiac output despite the regurgitant valve flow; left ventricular diastolic pressures remain normal. In contrast, with acute AR the regurgitant volume fills a small ventricle that has not had time to dilate, resulting in an acute increase in left ventricular diastolic pressure and a fall in forward cardiac output. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute AR results in the following pathophysiologic events:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The left ventricle cannot acutely increase total stroke volume, resulting in a decline in forward stroke volume and cardiac output. The decline in forward stroke volume may be exacerbated by a shortening of diastolic filling time due to the combination of early closure of the mitral valve (due to high end diastolic pressures) and tachycardia (caused by a decrease in forward flow and cardiac output). The net effect is often profound hypotension and cardiogenic shock.",
"     </li>",
"     <li>",
"      Left ventricular diastolic pressure rises sharply, with equalization of end-diastolic aortic and left ventricular pressures in severe cases. The elevated left ventricular end-diastolic pressure leads to elevated left atrial and pulmonary venous pressures, which can lead to pulmonary edema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=see_link\">",
"       \"Hemodynamics of valvular disorders as measured by cardiac catheterization\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These effects may be more pronounced in patients with a small, noncompliant left ventricular cavity due to preexisting left ventricular hypertrophy due, for example, to aortic dissection in patients with underlying systemic hypertension or acute AR after balloon valvotomy for congenital aortic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20022/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe acute AR commonly presents catastrophically with sudden cardiovascular collapse. Other presenting symptoms are related to the cause of acute AR (eg, signs and symptoms of endocarditis or aortic dissection). However, in some cases, acute AR is the first clue suggesting one of these diagnoses. Aortic dissection should always be suspected in patients with AR and chest or back pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As will be described, many of the characteristic findings of chronic AR are less prominent or absent on physical examination and imaging in patients with acute AR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manifestations of cardiogenic shock usually dominate in patients with severe acute AR. These include profound hypotension, pallor, diaphoresis, occasional cyanosis, and other signs of peripheral vasoconstriction. The pulse pressure is normal or may be reduced, but the pulse is usually weak, thready, and rapid. The cardiac apex is generally not displaced and is not hyperdynamic.",
"   </p>",
"   <p>",
"    If aortic dissection is the cause, an inequality of pulses and blood pressure between the left and right arms may be observed. However, this finding may not be appreciated in the setting of profound hypotension.",
"   </p>",
"   <p>",
"    The peripheral manifestations of chronic AR, associated with an increased pulse pressure such as Traube's sign, Duroziez's murmur, and water hammer (Corrigan) pulses, are less apparent or may be entirely absent with acute AR. This difference from chronic AR is due to the fact that left ventricular stroke volume and diastolic filling volume are not increased with acute regurgitation. As a result, the wide pulse pressure seen in chronic AR is generally not seen. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathophysiology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cardiac auscultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute AR alters the quality of most of the heart sounds:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The early closure of the mitral valve generally produces a soft or absent S1, which can occasionally be heard in mid-diastole.",
"     </li>",
"     <li>",
"      The aortic component of S2 is often soft, while P2 is usually increased, reflecting pulmonary hypertension.",
"     </li>",
"     <li>",
"      An S3 is frequently heard but an S4 is absent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to the high pitched holodiastolic decrescendo murmur of chronic AR, the murmur with acute AR is a low pitched early diastolic murmur beginning after S2 (",
"    <a class=\"graphic graphic_movie graphicRef77962 \" href=\"UTD.htm?0/12/195\">",
"     movie 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef56371 \" href=\"UTD.htm?41/61/42960\">",
"     movie 2",
"    </a>",
"    ). The murmur, however, may not be heard, especially when the diastolic gradient between the aorta and left ventricle lessens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systolic murmur resulting from the increased volume of blood crossing the aortic valve may be heard, but is usually not loud. The combination of a soft systolic and a low-pitched diastolic murmur often produces a \"to-and-fro\" murmur at the cardiac base in acute AR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific electrocardiographic changes with acute AR. Nonspecific ST and T wave abnormalities are common due to the markedly elevated left ventricular pressures. If acute AR is due to aortic dissection, involvement of the right coronary artery can result in ECG findings of acute myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=see_link\">",
"     \"Right ventricular myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;The size of the left atrium and ventricle on the chest radiograph is generally normal in acute AR, although there may be a slight increase in the left ventricular silhouette. Radiographic evidence of heart failure and pulmonary edema include the redistribution of blood flow to the upper lobes and an increase in size and amount of the pulmonary vasculature.",
"   </p>",
"   <p>",
"    In acute AR caused by aortic dissection, the cardiac silhouette may be markedly enlarged due to pericardial effusion, and a widened mediastinum may result from aortic root dilation (normal diameter &le;35 mm).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is diagnostic in acute AR. The cause of aortic regurgitation can be determined by identification of characteristic findings such as those of aortic valve endocarditis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=see_link\">",
"     \"Role of echocardiography in infective endocarditis\"",
"    </a>",
"    ) or aortic dissection (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\", section on 'Imaging'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Color Doppler echocardiography demonstrates the backflow of blood across the aortic valve in diastole, but it is rarely necessary to calculate regurgitant volume or regurgitant orifice area. Instead, the presence of severe acute AR is based upon the following findings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20022/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A vena contracta width (narrowest segment of the color flow jet) &gt;6 mm.",
"     </li>",
"     <li>",
"      For central severe jets, the jet width in the left ventricular outflow tract is large (&ge;65 percent of the outflow tract width). For severe eccentric jets, the visualized jet width is variable.",
"     </li>",
"     <li>",
"      A dense continuous wave Doppler signal with a steep diastolic slope (pressure half-time &lt;200 msec) due to rapid equalization of diastolic pressures in the aorta and left ventricle. Other signs of rapid pressure equilibration are a short mitral deceleration time (&lt;150 ms) and premature closure of the mitral valve. In very severe cases, the end-diastolic velocity approaches zero indicating that aortic diastolic pressure and LV end diastolic pressure are nearly equal [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20022/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of holodiastolic flow reversal in the descending thoracic and proximal abdominal aorta.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Echocardiographic imaging also permits evaluation of left ventricular size and systolic function, which are usually normal with acute regurgitation and may provide information on the possible cause of valve dysfunction (eg, evidence for aortic dilatation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dissection or the presence of valvular vegetations). Transesophageal imaging is more accurate than transthoracic imaging for both of these diagnoses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=see_link\">",
"     \"Role of echocardiography in infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other imaging modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the patient with acute AR who has a suspected aortic dissection, either CT imaging or transesophageal echocardiography can be performed since the sensitivity and specificity of these two approaches are similar. CT imaging may help delineate the anatomy by identifying the intimal flap, as well as the site and extent of dissection and the possible involvement of major branch arteries. MR imaging is of less utility in the acute setting due to less availability and concerns about limitations of clinical monitoring and patient accessibility while the patient is in the MR scanner. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the gravity of the patient's condition with severe acute AR and the severity of the hemodynamic alterations, there is usually no time to perform cardiac catheterization or contrast angiography. Emergency valve surgery should not be delayed for coronary angiography if there is severe acute AR with hemodynamic instability. If the patient is reasonably stable, coronary angiography is useful in patients with known coronary artery disease, particularly in those with coronary artery bypass grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20022/abstract/9\">",
"     9",
"    </a>",
"    ]. Aortography is indicated only when the diagnosis cannot be established by noninvasive imaging. Aortography can confirm the presence of severe wide open AR as well as identify aortic dissection and associated aortic root widening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment for acute severe AR is emergency aortic valve replacement or repair. If there is any delay in surgery, temporary stabilization may be attempted in the intensive care unit using intravenous vasodilators, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    , and possibly inotropic agents such as dopamine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    in an attempt to enhance forward flow and lower left ventricular end-diastolic pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20022/abstract/9\">",
"     9",
"    </a>",
"    ]. An intraaortic balloon pump is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    because inflation of the balloon in diastole will worsen the severity of AR.",
"   </p>",
"   <p>",
"    A related issue is the management of acute mild or moderate AR. When due to an aortic dissection, aortic valve resuspension along with graft replacement of the ascending aorta often allows preservation of the native valve with resolution of valve incompetence. When due to endocarditis, antibiotic therapy alone may be sufficient unless the patient has another indication for valve replacement (",
"    <a class=\"graphic graphic_table graphicRef76266 \" href=\"UTD.htm?37/50/38699\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20022/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link\">",
"     \"Surgery for native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The surgical approach depends upon the cause of AR, ranging from a composite valve and root replacement for endocarditis with a paravalvular abscess, to valve resuspension for AR due to aortic dissection, to valve repair for rupture of a fenestrated cusp. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25449?source=see_link\">",
"     \"Management of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of factors affect the risk for in-hospital mortality after aortic valve replacement. A standard way of stratifying operative risk is by using one of the available validated risk stratification models. The risk models are helpful in the evaluation and counseling of individual patients and planning perioperative care. Models have been developed to estimate risk of in-hospital mortality and complications following aortic or mitral valve surgery with or without coronary artery bypass graft surgery (CABG). However, these models have limited accuracy and they do not account for all important prognostic variables. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/5/7252?source=see_link\">",
"     \"Estimating the mortality risk of valvular surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H277956508\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Causes of acute native valve aortic regurgitation (AR) include endocarditis, aortic dissection, rupture of a congenitally fenestrated cusp, traumatic leaflet rupture, and iatrogenic valve injury during aortic balloon valvotomy or a failed surgical valve repair. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of acute prosthetic aortic regurgitation (AR) include mechanical valve thrombosis or disk escape. With bioprosthetic valves, AR may occur with valve rupture adjacent to areas of leaflet calcification or leaflet destruction due to endocarditis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe acute AR commonly presents catastrophically with sudden cardiovascular collapse. Other presenting symptoms and signs are related to the cause of acute AR (eg, signs and symptoms of endocarditis or aortic dissection). Aortic dissection should always be suspected in patients with AR and chest or back pain. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute AR is associated with a low pitched early diastolic murmur although this murmur may not be heard with a reduced diastolic gradient between the aorta and the left ventricle. With acute AR the increased pulse pressure and associated signs seen with chronic AR are typically absent. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echocardiography is diagnostic in acute AR and enables identification of its cause. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment for acute severe AR is emergency aortic valve replacement or repair. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20022/abstract/1\">",
"      Stout KK, Verrier ED. Acute valvular regurgitation. Circulation 2009; 119:3232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20022/abstract/2\">",
"      Mokadam NA, Stout KK, Verrier ED. Management of acute regurgitation in left-sided cardiac valves. Tex Heart Inst J 2011; 38:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20022/abstract/3\">",
"      Fedak PW, Verma S, David TE, et al. Clinical and pathophysiological implications of a bicuspid aortic valve. Circulation 2002; 106:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20022/abstract/4\">",
"      Blaszyk H, Witkiewicz AJ, Edwards WD. Acute aortic regurgitation due to spontaneous rupture of a fenestrated cusp: report in a 65-year-old man and review of seven additional cases. Cardiovasc Pathol 1999; 8:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20022/abstract/5\">",
"      Pr&ecirc;tre R, Faidutti B. Surgical management of aortic valve injury after nonpenetrating trauma. Ann Thorac Surg 1993; 56:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20022/abstract/6\">",
"      Onorati F, De Santo LS, Carozza A, et al. Marfan syndrome as a predisposing factor for traumatic aortic insufficiency. Ann Thorac Surg 2004; 77:2192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20022/abstract/7\">",
"      Isner JM. Acute catastrophic complications of balloon aortic valvuloplasty. The Mansfield Scientific Aortic Valvuloplasty Registry Investigators. J Am Coll Cardiol 1991; 17:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20022/abstract/8\">",
"      Roberts WC, Ko JM, Moore TR, Jones WH 3rd. Causes of pure aortic regurgitation in patients having isolated aortic valve replacement at a single US tertiary hospital (1993 to 2005). Circulation 2006; 114:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20022/abstract/9\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20022/abstract/10\">",
"      Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20022/abstract/11\">",
"      Grande RD, Katz WE. Acute aortic regurgitation secondary to disk embolization of a Bj&ouml;rk-Shiley prosthetic aortic valve. J Am Soc Echocardiogr 2011; 24:350.e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20022/abstract/12\">",
"      Saranteas T, Christodoulaki K, Rinaki D, Kostopanagiotou G. Transthoracic echocardiography for the identification of acute aortic regurgitation in the intensive care unit. J Cardiothorac Vasc Anesth 2011; 25:204.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8166 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-4DC6258CCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_35_20022=[""].join("\n");
var outline_f19_35_20022=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H277956508\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cardiac auscultation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other imaging modalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H277956508\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8166\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8166|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?0/12/195\" title=\"movie 1\">",
"      Aortic regurgitation as heard at the lower left sternal border",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?41/61/42960\" title=\"movie 2\">",
"      Aortic regurgitation as heard at the apex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8166|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/50/38699\" title=\"table 1\">",
"      Surgery native valve IE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=related_link\">",
"      Clinical manifestations and diagnosis of bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18249?source=related_link\">",
"      Complications and outcome of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/29/25050?source=related_link\">",
"      Course and management of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/40/2697?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/5/7252?source=related_link\">",
"      Estimating the mortality risk of valvular surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=related_link\">",
"      Hemodynamics of valvular disorders as measured by cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25449?source=related_link\">",
"      Management of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39411?source=related_link\">",
"      Percutaneous aortic valvotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/57/922?source=related_link\">",
"      Right ventricular myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/8/20617?source=related_link\">",
"      Role of echocardiography in infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=related_link\">",
"      Surgery for native valve endocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_35_20023="Prostate anatomy";
var content_f19_35_20023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54803&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 597px\">",
"   <div class=\"ttl\">",
"    Prostate anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 577px; height: 599px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The prostate gland is a walnut-shaped structure located at the base of the urinary bladder. The prostate gland is composed of both glandular and muscular tissue. Secretions from the prostate, vas deferens and seminal vesicle empty into the prostatic urethra.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_35_20023=[""].join("\n");
var outline_f19_35_20023=null;
var title_f19_35_20024="Clinical practice guidelines";
var content_f19_35_20024=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical practice guidelines",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/35/20024/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/35/20024/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/35/20024/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/35/20024/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/35/20024/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/35/20024/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/35/20024/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical practice guidelines are recommendations for clinicians about the care of patients with specific conditions. They should be based upon the best available research evidence and practice experience.",
"   </p>",
"   <p>",
"    The Institute of Medicine defines clinical practice guidelines as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &ldquo;&hellip;statements that include recommendations, intended to optimize patient care, that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options&rdquo; [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on this definition, guidelines have two parts:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The foundation is a systematic review of the research evidence bearing on a clinical question, focused on the strength of the evidence on which clinical decision-making for that condition is based.",
"     </li>",
"     <li>",
"      A set of recommendations, involving both the evidence and value judgments regarding benefits and harms of alternative care options, addressing how patients with that condition should be managed, everything else being equal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, the US Preventive Services Task Force 's recommendations for",
"    <a class=\"external\" href=\"file://www.uspreventiveservicestaskforce.org/uspstf/uspscolo.htm\">",
"     colorectal cancer screening",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/2\">",
"     2",
"    </a>",
"    ] were published with two separate background papers: a systematic review with 129 references [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/3\">",
"     3",
"    </a>",
"    ] and a decision analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Formal advice on how clinicians should manage patients is not new. Local opinion leaders or the authors of widely-circulated review articles have had a powerful influence on practice decisions. What has changed about modern clinical practice guidelines is that they are based on systematic reviews of the evidence, are often endorsed by national organizations, undergo intensive review, and are circulated across international boundaries and specialties.",
"   </p>",
"   <p>",
"    Guidelines have largely focused on the effectiveness of interventions. More recently, they have paid more attention to the size of the effect and the balance between effects on the one hand and harms and costs on the other, as well as on the feasibility of following guidelines. Another emerging development is the concept of individualized guidelines, whereby risk factors specific to the individual patient, rather than population-based risk factors, are incorporated into the tool weighing risks and benefits to guide treatment decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/5\">",
"     5",
"    </a>",
"    ]. While such individualized guidelines have the potential to improve quality of care and lower healthcare costs, limitations to their practice application at this time include the availability of patient-specific data, validated disease models and risk calculators, and the potential impact on workflow. Guidelines developed in the United Kingdom by the National Institute for Health and Clinical Excellence (NICE) involve patients and caregivers in the development process and explicitly include patient choice and cost effectiveness as factors in determining recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     USE AND USERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines are intended for clinicians, to help them take better care of patients. However, others involved in the health care system also use them, for better or worse. Insurers and administrators may use guidelines to set policies on quality and payment for care. As an example, \"pay for performance\" (also called \"pay for quality\") programs are being developed to link physician payment to quality of care, as measured by guideline-derived parameters of clinical care. They are an effort to deal with rising costs and the need for quality improvement. These programs are based on explicit standards for performance, a new kind of guideline. The concept is popular but there is not a strong body of research evidence to confirm its promise [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lawyers may use well-accepted national guidelines in malpractice litigation, arguing that physicians who have not followed such guidelines without a good reason are negligent. Malpractice claims of this sort are not commonplace so far, in part because of a multiplicity of guidelines for the same condition, which tend to differ from each other, so than none can be taken as a community standard.",
"   </p>",
"   <p>",
"    Guidelines are suggestions for care, not rules. There will always be individual patients who should be managed differently. Legitimate reasons for this include biologic differences in drug metabolism, immune response, or genetic endowment; the presence of comorbid conditions; available resources determined by the social and economic environment of medicine at the local level; and patient preferences [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/8\">",
"     8",
"    </a>",
"    ]. However, most patients do fit the recommendations in guidelines, and this should be reflected in practice patterns.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RECOGNIZING CREDIBLE GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thousands of guidelines have been published. They vary in quality; some are masterpieces of clinical scholarship and judgment while others are naive and self-serving. The most trustworthy guidelines can be recognized by best practices for the guideline development identified by the Institute of Medicine (IOM) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Has an explicit description of development and funding processes that is publicly accessible",
"     </li>",
"     <li>",
"      Follows a transparent process that minimizes bias, distortion, and conflicts of interest",
"     </li>",
"     <li>",
"      Is developed by a multidisciplinary panel comprising clinicians; methodological experts; and representatives, including a patient or consumer, of populations expected to be affected by the guideline",
"     </li>",
"     <li>",
"      Uses rigorous systematic evidence review and considers quality, quantity, and consistency of the aggregate of available evidence",
"     </li>",
"     <li>",
"      Summarizes evidence (and evidentiary gaps) about potential benefits and harms relevant to each recommendation",
"     </li>",
"     <li>",
"      Explains the parts that values, opinion, theory, and clinical experience play in deriving recommendations",
"     </li>",
"     <li>",
"      Provides a rating of the level of confidence in the evidence underpinning each recommendation and a rating of the strength of each recommendation",
"     </li>",
"     <li>",
"      Undergoes extensive external review that includes an open period for public comment",
"     </li>",
"     <li>",
"      Has a mechanism for revision when new evidence becomes available",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American Cancer Society, an important source of cancer screening guidelines, has revised its process for developing guidelines on the basis of the IOM recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the IOM has noted that all of these criteria should be met in order for a guideline to be judged trustworthy, the issue of measuring the &ldquo;trustworthiness&rdquo; of guidelines, based on how closely they adhere to these or other standards, has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/11\">",
"     11",
"    </a>",
"    ]. Additionally, questions have been raised about the feasibility of implementing all of the IOM&rsquo;s criteria in settings where resources may be constrained. An international network, the",
"    <a class=\"external\" href=\"file://www.g-i-n.net/\">",
"     Guidelines International Network (G-I-N),",
"    </a>",
"    representing 46 countries and 93 organizations, is working to develop consensus regarding minimal standards for guideline development [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Expertise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines prepared by panels representing the full range of expertise bearing on the clinical question are more likely to avoid the biases and blind spots of members who are all from a given specialty [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/13\">",
"     13",
"    </a>",
"    ]. These panels should represent a wide range of expertise and may include, in addition to physicians, representatives from allied health sciences, public health specialists, decision analysts, economists, consumers, and ethicists. Expertise in interpreting research evidence is a necessary component of the panel. It can be contributed by members who also have other expertise, or a methods expert can be included.",
"   </p>",
"   <p>",
"    Guidelines prepared by the US Preventive Services Task Force make special effort to balance the interests of its guidelines panels and are carefully prepared [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/14\">",
"     14",
"    </a>",
"    ]. In the United Kingdom, evidence-based guidelines developed by the National Clinical Guideline Centre (NICE) for implementation in the National Health Service are also rigorously developed over a period of about 2.5 years from inception to release and incorporate decisions based upon clinical and cost-effectiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/15\">",
"     15",
"    </a>",
"    ]. Some guidelines prepared by specialty and subspecialty societies involve a narrower spectrum of interest limited to members in the society [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Evidence based",
"    </span>",
"    &nbsp;&mdash;&nbsp;Credible guidelines are based on a systematic review of published research that is likely to include reports of all scientifically credible studies that bear on the question at hand. The systematic review should follow explicit ground rules for identifying all relevant studies and judging their scientific strength and should make transparent the rationale for their decisions. Expert opinion and usual practice not supported by research evidence may be included, but should be labeled as such and not take precedence over stronger evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/17\">",
"     17",
"    </a>",
"    ]. The process of developing guidelines can be used as an impetus to encourage clinical research when evidence is not available [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    High-quality evidence is often not available. In a review of guidelines from the Infectious Diseases Society of American (IDSA), for example, only 14 percent of the 4000 recommendations were supported by the highest-level evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/20\">",
"     20",
"    </a>",
"    ]. A study of American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    College of Cardiology guidelines found that nearly half of recommendations were based on the lowest level of evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even when data from well-designed and well-implemented randomized controlled trials are available, they often are not directly applicable to the populations, interventions, or outcomes addressed by the guideline being developed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The aim of practice guidelines to optimize patient management may be even more relevant in circumstances where evidence is equivocal and the clinician is less certain about the choice of strategy. In such circumstances, the synthesis of carefully weighed opinions of experts may be particularly helpful, considered in the context of individual patient factors and adapted as needed. Transparency is essential, so that guidelines based upon weak evidence are clearly identified as such and modified when evidence changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Grading guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some guidelines panels grade their recommendations. A common approach is to grade the strength of the evidence and the strength of the recommendation separately.",
"   </p>",
"   <p>",
"    The US Preventive Services Task Force (USPSTF) has used a rating system that is uniform across the hundreds of conditions it reviews and features separate rating systems for strength of recommendations and quality of evidence (",
"    <a class=\"graphic graphic_table graphicRef75920 \" href=\"UTD.htm?32/29/33243\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73780 \" href=\"UTD.htm?14/59/15291\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=see_link\">",
"     \"Overview of preventive medicine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/23\">",
"     23",
"    </a>",
"    ] appears to be gaining increasing acceptance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. In GRADE, grades have two components, a number (1 or 2) reflecting the strength of the recommendation and a letter (A, B, C, or D) reflecting the quality of the evidence supporting that recommendation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Strength of the recommendation:",
"      </strong>",
"      A Grade 1 recommendation is a strong recommendation to do (or not do) something, where the benefits clearly outweigh the risks (or vice versa) for most patients. A Grade 2 recommendation is a weaker recommendation, where the risks and benefits are more closely balanced or are more uncertain.",
"     </li>",
"     <li>",
"      <strong>",
"       Quality of evidence",
"      </strong>",
"      : Assessment of evidence quality in GRADE reflects confidence in the estimates of benefits, harms, and burdens. GRADE can be implemented with either three or four levels of evidence quality; UpToDate uses three levels (A, B, or C). Grade A evidence means high-quality evidence from well-performed randomized controlled trials, or other overwhelming evidence (such as well-executed observational studies with very strong effects). Grade B signifies moderate-quality evidence from randomized trials with important limitations, or from other study designs with special strength. Grade C evidence means low-quality evidence from observational studies, or from controlled trials with very serious limitations (",
"      <a class=\"graphic graphic_table graphicRef52003 \" href=\"UTD.htm?5/38/5741\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Consider outcomes and implementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines should take into account not only whether an effect of an intervention exists beyond chance but also other clinically-relevant factors, such as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The magnitude of effect",
"     </li>",
"     <li>",
"      Harms from the intervention",
"     </li>",
"     <li>",
"      Convenience and side effects",
"     </li>",
"     <li>",
"      The clinical skills necessary to carry out the intervention successfully",
"     </li>",
"     <li>",
"      Patient preferences",
"     </li>",
"     <li>",
"      Cost",
"     </li>",
"     <li>",
"      Cost-effectiveness",
"     </li>",
"     <li>",
"      The work force necessary to implement the recommendations",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Recency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most guidelines are produced only once or, as with the USPSTF or National Cholesterol Education Program (NCEP), are updated at several-year intervals. In fast-moving fields, such as treatment of HIV infection, these guidelines may be out of date in less than a year.",
"   </p>",
"   <p>",
"    In a study of guidelines sponsored by the US Agency for Healthcare Research and Quality, more than three-fourths of guidelines needed updating [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/29\">",
"     29",
"    </a>",
"    ]. A study of 100 quantitative systematic reviews found that new findings with impact on the review outcome occurred within two years of publication for 23 percent of the reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/30\">",
"     30",
"    </a>",
"    ]. The median time for &ldquo;survival&rdquo; of an analysis was 5.5 years. Thus, it is reasonable to assume that any guideline that has not undergone review with updating as needed within five years of publication, in the absence of strong justification, should not be accepted as current.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sponsoring society",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statements formally endorsed by respected national bodies are subject to scrutiny by health professionals and sometimes by the public through coverage in the popular media. These organizations have a strong incentive to safeguard their reputation by having their guidelines stand up to scrutiny. However, the imprimatur of a sponsoring organization does not necessarily guarantee quality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Review",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best guidelines undergo careful review by representatives of the sponsoring organization other than panel members. Better yet, experts outside the organization are asked to review and endorse the guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8828414\">",
"    <span class=\"h2\">",
"     Conflict of interest",
"    </span>",
"    &nbsp;&mdash;&nbsp;The guideline should report financial conflicts of interest (COI) bearing on the guideline for each member of the panel [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines recommends written disclosure of any commercial, noncommercial, intellectual, institutional, or patient-public activity pertinent to the guideline scope [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/1\">",
"     1",
"    </a>",
"    ]. It also recognized that for some guidelines, a degree of COI might be unavoidable in panel participants (such as relevant clinical specialists whose income is related to providing services pertinent to the guideline) but that these members should be a minority of the panel and should not be chairs or co-chairs.",
"   </p>",
"   <p>",
"    While it is recognized that transparency is essential when participants in the guidelines preparation process have conflicts of interest, it is less clear how best to adapt the process to avoid bias related to any COI [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/31\">",
"     31",
"    </a>",
"    ]. Clinicians with notable expertise in an area are both more likely to be sought out to participate in developing relevant guidelines and to participate in industry-sponsored activities such as speaker&rsquo;s bureaus or advisory panels. In various reports, the frequency of financial COIs among authors of clinical guidelines ranges from 35 to 87 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     QUALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many guidelines do not meet current standards for quality (",
"    <a class=\"graphic graphic_table graphicRef68090 \" href=\"UTD.htm?5/12/5324\">",
"     table 4",
"    </a>",
"    ). In a study of 279 guidelines by 69 different developers, the overall adherence to standards was 43.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/35\">",
"     35",
"    </a>",
"    ]. The greatest improvement was needed in the identification, evaluation, and synthesis of the scientific evidence. A study of guidelines prepared by specialty societies reported that most of the 413 guidelines studied did not meet criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/36\">",
"     36",
"    </a>",
"    ]. Performance improved from 1988 to 1998, but by 1998 only 5 percent met the three main criteria: description of the type of stakeholder; searches for published studies; and explicit grading of the strength of recommendations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Disagreement among guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines on the same clinical question by different expert groups often disagree. Usually the differences are minor; with screening guidelines, for example, they might differ on the age at which screening should begin and end or the time interval between screening examinations. Uncommonly, recommendations are very different. Two major guidelines for colorectal cancer screening were published within several months of each other [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/3,37\">",
"     3,37",
"    </a>",
"    ]. One was by the US Preventive Services Task Force and the other by a consortium of the American Cancer Society, the US Multisociety Task Force, and the American College of Radiology. The two guidelines included different sets of screening test options (three options for one, seven for the other) and preferences (the ACS guidelines stated that tests that detected adenomas were preferred over those detecting cancers only). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link&amp;anchor=H12#H12\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\", section on 'Guidelines for average risk screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other examples are acrimonious public criticisms of guidelines by the US Preventive Services Task Force that diverged from some professional society guidelines and did not recommend mammography screening for women 40 to 49 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/38\">",
"     38",
"    </a>",
"    ] and that gave PSA screening for prostate cancer a low grade [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/39\">",
"     39",
"    </a>",
"    ]. A review of eight guidelines on screening asymptomatic patients for peripheral arterial disease found conflicting recommendations from different organizations, with differing interpretations of the evidence base that was mostly related to the role of testing in symptomatic patients, but not to asymptomatic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disagreement may be a barrier to acceptance of guidelines. However, in one study of this question, the extent to which clinicians agreed with each other regarding intervals for cancer screening was not related to the extent to which guidelines agreed on recommended screening intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disagreement among recommendations is not necessarily a sign of poor quality. A weak evidence base may lead to various conclusions. Guidelines may disagree because of the value system of the panel that developed them. One study showed that surgeons tended to favor more aggressive cancer screening intervals than family physicians and internists and that gynecologists favored more aggressive screening for cancers occurring in women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/41\">",
"     41",
"    </a>",
"    ]. The best possible care of patients may also vary according to availability of resources, health priorities, and social environment. As an example, screening guidelines tend to be less aggressive in Canada and the UK than they are in the US.",
"   </p>",
"   <p>",
"    Guidelines can differ for bad reasons too. Politics have intruded on some guidelines processes, notably those for breast cancer in women under age 50 years. Some panel members or sponsoring societies have a strong financial conflict of interest. Some panels do not include members with expertise in the interpretation of research evidence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pluralism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States has opted for guidelines prepared by a variety of competing organizations, most in the private sector, rather than a single version prepared by the federal government. While the multiplicity of guidelines, and their differences, can be confusing, the absence of a single standard for practice allows for innovation and protects physicians from being held to a single community standard when there is absence of strong evidence on the best practice.",
"   </p>",
"   <p>",
"    Other countries have a single organization developing guidelines. The",
"    <a class=\"external\" href=\"file://nice.org.uk/\">",
"     National Institute for Health and Clinical Effectiveness (NICE)",
"    </a>",
"    develops guidelines in the UK and",
"    <a class=\"external\" href=\"file://www.iqwig.de/index.2.en.html\">",
"     the Institute for Quality and Efficiency in Health Care",
"    </a>",
"    does this in Germany.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     FINDING GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A",
"    <a class=\"external\" href=\"file://www.guideline.gov\">",
"     National Guideline Clearinghouse",
"    </a>",
"    website is maintained by the Federal Agency for Healthcare Quality in conjunction with the American Medical Association and the American Association of Health Plans. This database does not include all guidelines but guidelines from most major medical organizations are included. Guidelines can also be found at the Web sites of the sponsoring organizations (",
"    <a class=\"graphic graphic_table graphicRef80337 \" href=\"UTD.htm?4/7/4219\">",
"     table 5",
"    </a>",
"    ), and by entering \"clinical practice guidelines\" into search engines such as",
"    <a class=\"external\" href=\"file://savvysearch.com/\">",
"     savvysearch.com",
"    </a>",
"    ,",
"    <a class=\"external\" href=\"file://metacrawler.com/\">",
"     metacrawler.com",
"    </a>",
"    ,",
"    <a class=\"external\" href=\"file://googlescholar.com/\">",
"     googlescholar.com",
"    </a>",
"    , or",
"    <a class=\"external\" href=\"file://northernlight.com/\">",
"     northernlight.com",
"    </a>",
"    . &ldquo;Practice guideline&rdquo; can also be set as a limit term for type of article when using",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/pubmed\">",
"     PubMed",
"    </a>",
"    to search the US National Library of Medicine. None of these databases sorts the guidelines by quality. The National Guideline Clearing House is planning to tag the guidelines it lists with markers of quality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4807734\">",
"    <span class=\"h1\">",
"     APPROPRIATE USE CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate use criteria (AUC, sometimes referred to as &ldquo;appropriateness criteria&rdquo;) are a variation on clinical practice guidelines, but differ in several ways [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Appropriateness is tailored as much as possible to the specific characteristics of individual patients.",
"     </li>",
"     <li>",
"      AUC cover a broader array of specific conditions, sometimes hundreds for a given test or treatment decision, to encompass the majority of practice situations. Appropriateness may relate to individual patient demographic characteristics, clinical history, risk scores,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms and signs.",
"     </li>",
"     <li>",
"      AUC are based upon scientific evidence where possible but, in part as a result of the breadth of specific clinical conditions addressed, rely more on expert opinion than do rigorous clinical practice guidelines.",
"     </li>",
"     <li>",
"      Panels that formulate AUC are typically comprised of representatives from the specialties that manage patients with the clinical question under consideration.",
"     </li>",
"     <li>",
"      Specific clinical scenarios (or potential indications for an intervention) are rated on a 1 to 9 scale by each panelist before and after a group face-to-face discussion, and the median of the panel ratings is then used to designate&nbsp;each clinical scenario as appropriate, uncertain, or inappropriate.",
"     </li>",
"     <li>",
"      AUC are intended not only to help clinicians make sound clinical decisions, but also to educate patients and improve the effectiveness, efficiency, and equality of care.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Implementation of some AUC has been facilitated by the development of calculators or tables, in which the clinician can input specific patient information. As with guidelines, AUC are not intended to replace clinical judgment.",
"   </p>",
"   <p>",
"    The AUC approach has been used primarily by subspecialty societies concerned with cardiovascular, rheumatologic, and pulmonary conditions, and associated imaging procedures. AUC have also been developed for several surgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/43\">",
"     43",
"    </a>",
"    ]. AUC are included in the National Guidelines Clearing House.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ATTITUDES AND ACCEPTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, clinicians are most likely to accept recommendations from their own specialty society, less likely to trust those prepared by government agencies, and least likely to believe in guidelines prepared by managed care organizations and insurance companies. In one study of internists' attitudes toward guidelines, 82 percent had confidence in guidelines prepared by the American College of Physicians and only 6 percent in those prepared by Blue Cross and Blue Shield [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/44\">",
"     44",
"    </a>",
"    ]. Attitudes related to who prepared guidelines appear to be independent of the scientific validity of the guidelines themselves, although this has not been specifically studied.",
"   </p>",
"   <p>",
"    Clinicians disagree on whether clinical practice guidelines promote \"cook-book medicine\" with \"not enough recipes in the cookbook\" [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/45\">",
"     45",
"    </a>",
"    ] or evidence-based medicine. In one study of a national sample of internists, the majority believed that guidelines are good educational tools, a convenient source of advice, and are intended to improve the quality of care and decrease health care costs [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/44\">",
"     44",
"    </a>",
"    ]. However, a majority also believed that guidelines are biased, oversimplified, and rigid, likely to decrease physician reimbursement, challenge physician autonomy, and decrease physician satisfaction.",
"   </p>",
"   <p>",
"    Physicians are more likely to trust guidelines if they have had a hand in developing them. However, it is neither practical nor necessary for local physicians to build new guidelines from the ground up if guidelines by national groups already exist. Much of the work needed to assemble the evidence, which can take thousands of hours, has been done. Local physician groups should critically review guidelines prepared by national groups, even if they are well done, and consider modifying them to suit their local situation. The conditions of practice, resources, and patient preferences may be distinctive enough from practice to practice to lead to somewhat different recommendations. Also, local modifications of guidelines foster local buy-in.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3412726\">",
"    <span class=\"h2\">",
"     Potential benefits/problems of guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence-based, carefully developed and updated guidelines provide many potential benefits:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Synthesis of the literature by experts",
"     </li>",
"     <li>",
"      Clear recommendations for translating the evidence base into clinical application to foster best practice",
"     </li>",
"     <li>",
"      Opportunity to evaluate the outcomes of implementation in the &ldquo;real world&rdquo; setting",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, several aspects of guidelines and their implementation need to be recognized as potential problems:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The challenge of keeping guidelines updated when the literature changes",
"     </li>",
"     <li>",
"      The potential for inappropriate use of guidelines as tools for legal or restrictive administrative purposes",
"     </li>",
"     <li>",
"      Difficulty accessing guidelines at the point of care: many are lengthy, or specific components relevant to a patient are not readily searchable or retrievable",
"     </li>",
"     <li>",
"      Lack of coordination between guideline development groups, generating differing recommendations",
"     </li>",
"     <li>",
"      Potential for conflict of interests",
"     </li>",
"     <li>",
"      Application of guidelines developed to address a specific condition to patients with multiple morbidity [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EFFECTS OF GUIDELINES ON PRACTICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simply providing guidelines seems to improve practice, but the effects are small [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/47\">",
"     47",
"    </a>",
"    ]. It is clear that there are significant gaps between guidelines recommendations and practice. As an example, in one study of practice in the United States, it was estimated that 68,000 deaths could be prevented if six recommendations from guidelines for the management of heart failure were closely followed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/48\">",
"     48",
"    </a>",
"    ]. There are many reasons why clinicians do not adhere to guidelines recommendations. In one report using focus groups of general practitioners in the Netherlands to explore reasons why recommendations from 12 national guidelines were not followed, the most frequently perceived barriers to adoption were identified as disagreement with the recommendations, environmental factors based on organizational constraints, lack of knowledge of the recommendations, and unclear or ambiguous guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/49\">",
"     49",
"    </a>",
"    ]. In other studies, recommendations were more likely to be followed when they were supported by clear evidence, were compatible with existing norms and values, did not require new skills or change in practice routine, were less controversial, and were stated in specific actionable terms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the &ldquo;actionability&rdquo; of a guideline is an important attribute. While well-formulated guidelines can be an invaluable tool to guide best practice in medicine, they should not alone be considered a complete plan for quality improvement. Rather, they need to be delivered in the context of a program to engage patients and clinicians in appropriate decision-making, supported by implementation strategies involving systems enhancements, clinical reminders, other quality improvement and decision support tools, and outcomes measurement and feedback. However, even when such support is provided, it remains challenging to change clinician practice. In a randomized trial related to guidelines for the management of nonvariceal upper gastrointestinal bleeding, 43 hospitals were randomly assigned to an intervention (physicians received published consensus guidelines, algorithms, written reminders, and participated in multidisciplinary guideline education groups and case-based workshops) or control (received guidelines and algorithms) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/52\">",
"     52",
"    </a>",
"    ]. At one year, guideline adherence was not significantly different between the intervention and control hospitals, with adherence below 10 percent in both groups.",
"   </p>",
"   <p>",
"    Clinical practice guidelines generally are not intended as quality measures. Guidelines often do not adequately account for severity of illness, patient preferences, or clinical judgment to be able to be used as quality measures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/53\">",
"     53",
"    </a>",
"    ]. Experts in guidelines and evidence-based medicine urge clinicians to use them as a guide rather than as a set of rules or cookbook and to tailor clinical decisions to individual patients.",
"   </p>",
"   <p>",
"    The Institute of Medicine (IOM) does recommend that guidelines that are based upon strong evidence should be worded so that it is possible to evaluate whether care followed recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20024/abstract/54\">",
"     54",
"    </a>",
"    ]. To computer-aided clinical decision support can promote guideline adoption. The IOM suggests that guidelines be structured in format, vocabulary, and content to foster use of computer-aided decision supports by guidelines users.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical practice guidelines are recommendations for clinicians about the care of patients with specific conditions. Guideline development should involve a systematic review of the research evidence related to decision-making for the targeted",
"      <span class=\"nowrap\">",
"       condition/question,",
"      </span>",
"      and recommendations about patient management based on the evidence and value judgments that should be explicitly identified as such. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Guidelines are suggestions for care, not rules. There will always be individual patients who should be managed differently for reasons, including biologic differences (in drug metabolism, immune response, or genetic endowment); comorbidities; availability of resources and cultural differences; and patient preferences. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Use and users'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Guidelines vary widely in quality. Credible guidelines involve: development by a panel representing a full range of expertise; an unbiased systematic review of the evidence; grading the strength of the evidence and recommendation; incorporation of multiple relevant factors including feasibility, harms, costs, and patient preferences; a process for ongoing review and updating (",
"      <a class=\"graphic graphic_table graphicRef68090 \" href=\"UTD.htm?5/12/5324\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Recognizing credible guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Provision of guidelines should not be considered a complete plan for quality improvement. Additionally, practice guidelines are not intended as quality measures; experts in guidelines and evidence-based medicine urge clinicians to use them as a guide rather than as a set of rules or cookbook. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Effects of guidelines on practice'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Consensus report, Institute of Medicine. Clinical practice guidelines we can trust. March 23, 2011. file://www.iom.edu/Reports/2011/Clinical-Practice-Guidelines-We-Can-Trust.aspx (Accessed on January 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/2\">",
"      U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/3\">",
"      Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/4\">",
"      Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/5\">",
"      Eddy DM, Adler J, Patterson B, et al. Individualized guidelines: the potential for increasing quality and reducing costs. Ann Intern Med 2011; 154:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/6\">",
"      Peterson PN, Rumsfeld JS. The evolving story of guidelines and health care: does being NICE help? Ann Intern Med 2011; 155:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/7\">",
"      Rosenthal MB, Frank RG, Li Z, Epstein AM. Early experience with pay-for-performance: from concept to practice. JAMA 2005; 294:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/8\">",
"      Wilson MC, Hayward RS, Tunis SR, et al. Users' guides to the Medical Literature. VIII. How to use clinical practice guidelines. B. what are the recommendations and will they help you in caring for your patients? The Evidence-Based Medicine Working Group. JAMA 1995; 274:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/9\">",
"      Laine C, Taichman DB, Mulrow C. Trustworthy clinical guidelines. Ann Intern Med 2011; 154:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/10\">",
"      Brawley O, Byers T, Chen A, et al. New American Cancer Society process for creating trustworthy cancer screening guidelines. JAMA 2011; 306:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/11\">",
"      Ransohoff DF, Pignone M, Sox HC. How to decide whether a clinical practice guideline is trustworthy. JAMA 2013; 309:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/12\">",
"      Qaseem A, Forland F, Macbeth F, et al. Guidelines International Network: toward international standards for clinical practice guidelines. Ann Intern Med 2012; 156:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/13\">",
"      Sniderman AD, Furberg CD. Why guideline-making requires reform. JAMA 2009; 301:429.",
"     </a>",
"    </li>",
"    <li>",
"     AHRQ. The Guide to Clinical Preventive Services 2005. Available at: www.preventiveservices.ahrq.gov/#uspstf (Accessed on February 05, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/15\">",
"      Hill J, Bullock I, Alderson P. A summary of the methods that the National Clinical Guideline Centre uses to produce clinical guidelines for the National Institute for Health and Clinical Excellence. Ann Intern Med 2011; 154:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/16\">",
"      Brook RH. Practice guidelines: to be or not to be. Lancet 1996; 348:1005.",
"     </a>",
"    </li>",
"    <li>",
"     Fletcher RH. Building the Evidence. In: Implementing Clinical Practice Guidelines, Margolis CZ, Cretin S (Eds), AHA Press, Chicago 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/18\">",
"      Deresinski S, File TM Jr. Improving clinical practice guidelines--the answer is more clinical research. Arch Intern Med 2011; 171:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/19\">",
"      Li T, Vedula SS, Scherer R, Dickersin K. What comparative effectiveness research is needed? A framework for using guidelines and systematic reviews to identify evidence gaps and research priorities. Ann Intern Med 2012; 156:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/20\">",
"      Lee DH, Vielemeyer O. Analysis of overall level of evidence behind Infectious Diseases Society of America practice guidelines. Arch Intern Med 2011; 171:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/21\">",
"      Tricoci P, Allen JM, Kramer JM, et al. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 2009; 301:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/22\">",
"      McAlister FA, van Diepen S, Padwal RS, et al. How evidence-based are the recommendations in evidence-based guidelines? PLoS Med 2007; 4:e250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/23\">",
"      Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/24\">",
"      Guyatt G, Vist G, Falck-Ytter Y, et al. An emerging consensus on grading recommendations? ACP J Club 2006; 144:A8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/25\">",
"      Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest 2006; 129:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/26\">",
"      Guyatt GH, Oxman AD, Sch&uuml;nemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 2011; 64:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/27\">",
"      Guyatt GH, Helfand M, Kunz R. Comparing the USPSTF and GRADE approaches to recommendations. Ann Intern Med 2009; 151:363; author reply 363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/28\">",
"      Jaeschke R, Guyatt GH, Dellinger P, et al. Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive. BMJ 2008; 337:a744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/29\">",
"      Shekelle PG, Ortiz E, Rhodes S, et al. Validity of the Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated? JAMA 2001; 286:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/30\">",
"      Shojania KG, Sampson M, Ansari MT, et al. How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med 2007; 147:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/31\">",
"      Jones DJ, Barkun AN, Lu Y, et al. Conflicts of interest ethics: silencing expertise in the development of international clinical practice guidelines. Ann Intern Med 2012; 156:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/32\">",
"      Taylor R, Giles J. Cash interests taint drug advice. Nature 2005; 437:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/33\">",
"      Okike K, Kocher MS, Wei EX, et al. Accuracy of conflict-of-interest disclosures reported by physicians. N Engl J Med 2009; 361:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/34\">",
"      Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 2002; 287:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/35\">",
"      Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA 1999; 281:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/36\">",
"      Grilli R, Magrini N, Penna A, et al. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet 2000; 355:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/37\">",
"      Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008; 58:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/38\">",
"      Woolf SH. The 2009 breast cancer screening recommendations of the US Preventive Services Task Force. JAMA 2010; 303:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/39\">",
"      Chou R, LeFevre ML. Prostate cancer screening--the evidence, the recommendations, and the clinical implications. JAMA 2011; 306:2721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/40\">",
"      Ferket BS, Spronk S, Colkesen EB, Hunink MG. Systematic review of guidelines on peripheral artery disease screening. Am J Med 2012; 125:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/41\">",
"      Czaja R, McFall SL, Warnecke RB, et al. Preferences of community physicians for cancer screening guidelines. Ann Intern Med 1994; 120:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/42\">",
"      Patel MR, Spertus JA, Brindis RG, et al. ACCF proposed method for evaluating the appropriateness of cardiovascular imaging. J Am Coll Cardiol 2005; 46:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/43\">",
"      Lawson EH, Gibbons MM, Ingraham AM, et al. Appropriateness criteria to assess variations in surgical procedure use in the United States. Arch Surg 2011; 146:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/44\">",
"      Tunis SR, Hayward RS, Wilson MC, et al. Internists' attitudes about clinical practice guidelines. Ann Intern Med 1994; 120:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/45\">",
"      Parmley WW. Clinical practice guidelines. Does the cookbook have enough recipes? JAMA 1994; 272:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/46\">",
"      Guthrie B, Payne K, Alderson P, et al. Adapting clinical guidelines to take account of multimorbidity. BMJ 2012; 345:e6341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/47\">",
"      Farmer AP, L&eacute;gar&eacute; F, Turcot L, et al. Printed educational materials: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2008; :CD004398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/48\">",
"      Fonarow GC, Yancy CW, Hernandez AF, et al. Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J 2011; 161:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/49\">",
"      Lugtenberg M, Zegers-van Schaick JM, Westert GP, Burgers JS. Why don't physicians adhere to guideline recommendations in practice? An analysis of barriers among Dutch general practitioners. Implement Sci 2009; 4:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/50\">",
"      Burgers JS, Grol RP, Zaat JO, et al. Characteristics of effective clinical guidelines for general practice. Br J Gen Pract 2003; 53:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/51\">",
"      Grol R, Dalhuijsen J, Thomas S, et al. Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. BMJ 1998; 317:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/52\">",
"      Barkun AN, Bhat M, Armstrong D, et al. Effectiveness of disseminating consensus management recommendations for ulcer bleeding: a cluster randomized trial. CMAJ 2013; 185:E156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20024/abstract/53\">",
"      Sackett DL, Rosenberg WM, Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ 1996; 312:71.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Standards for Developing Trustworthy Clinical Practice Guidelines. file://iom.edu/Activities/Quality/ClinicPracGuide.aspx (Accessed on July 05, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2767 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-89768E4622-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_35_20024=[""].join("\n");
var outline_f19_35_20024=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      USE AND USERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RECOGNIZING CREDIBLE GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Expertise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Evidence based",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Grading guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Consider outcomes and implementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Recency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sponsoring society",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Review",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8828414\">",
"      Conflict of interest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      QUALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Disagreement among guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pluralism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FINDING GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4807734\">",
"      APPROPRIATE USE CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ATTITUDES AND ACCEPTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3412726\">",
"      Potential benefits/problems of guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EFFECTS OF GUIDELINES ON PRACTICE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2767\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2767|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/29/33243\" title=\"table 1\">",
"      USPSTF recommendation grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/59/15291\" title=\"table 2\">",
"      USPSTF evidence grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/38/5741\" title=\"table 3\">",
"      GRADE criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/12/5324\" title=\"table 4\">",
"      Clinical practice guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/7/4219\" title=\"table 5\">",
"      Guidelines on the internet",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_35_20025="Cecal bascule - CT scan";
var content_f19_35_20025=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Cecal bascule - CT scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 665px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A multiplanar CT examination was subsequently performed which demonstrated a cecal bascule (B and C, arrow). Note the normal location of the ascending colon (A, arrow), the region of fold with subsequent migration of the cecum in an anterior and cephalad direction (C, arrowhead). There is no evidence of vascular engorgement nor pericecal inflammatory change.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Farnum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_35_20025=[""].join("\n");
var outline_f19_35_20025=null;
var title_f19_35_20026="The effects of caffeine on reproductive outcomes in women";
var content_f19_35_20026=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The effects of caffeine on reproductive outcomes in women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/35/20026/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/35/20026/contributors\">",
"     Vicki Nisenblat, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/35/20026/contributors\">",
"     Robert J Norman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/35/20026/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/35/20026/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/35/20026/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/35/20026/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/35/20026/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caffeine is the most popular pharmacologically active substance consumed and one of the most heavily researched commodities in the world. It is a stimulant, and is often used to enhance mental alertness.",
"   </p>",
"   <p>",
"    Although there is no high quality evidence that a modest level of caffeine consumption has adverse effects on fertility or pregnancy outcome, putative beliefs about a relationship between caffeine intake and adverse reproductive outcomes are common, and caffeine consumption is often perceived to be an unhealthy habit. The consumption of caffeinated beverages has been implicated in fertility problems, while consumption during pregnancy has been associated with an increased risk of miscarriage, congenital malformations, fetal growth restriction, stillbirth, and long-term behavioral effects in offspring. The biologic rationale for these associations is caffeine's ability to accumulate in fetal tissues and produce diverse pharmacologic effects that could interfere with fetal growth and development [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the relationship between caffeine intake and reproductive issues in women. The physiological effects of caffeine and caffeinated beverages and the effects of caffeine on specific disease processes, including insulin resistance, cancer, cardiovascular disease, and mortality are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38375?source=see_link\">",
"     \"Cardiovascular effects of caffeine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17498?source=see_link\">",
"     \"Benefits and risks of caffeine and caffeinated beverages\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SOURCES OF CAFFEINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caffeine originates in more than 60 plants, occurs naturally in various food products and beverages (including coffee, tea, chocolate, cocoa products, colas), and is added to some soft drinks and most \"energy\" drinks. Caffeine is also present in some prescription and over-the-counter medications, such as cold and flu remedies, allergy and headache treatments, diet pills, diuretics, and stimulants. Increasingly, caffeine is now present as an additive in snack foods, sports performance supplements, and dietary supplements. Examples of the caffeine content of various products can be found online (eg,",
"    <a class=\"external\" href=\"file://www.cspinet.org/new/cafchart.htm\">",
"     file://www.cspinet.org/new/cafchart.htm",
"    </a>",
"    ) and in the table (",
"    <a class=\"graphic graphic_table graphicRef79304 \" href=\"UTD.htm?30/43/31422\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Coffee, tea, cocoa and carbonated soft drinks are the main sources of caffeine intake. Consumption varies throughout the world, and is influenced by culture, individual preferences, availability, and advertising. Coffee contains 50 to 70 percent more caffeine than tea and other products, accounting for the main source of caffeine in many populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CAFFEINE CONSUMPTION IN WOMEN OF REPRODUCTIVE AGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of daily caffeine intake vary widely, both worldwide and within individual countries, due to the many significant difficulties in ascertaining caffeine consumption. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Quality of existing evidence and methodological considerations'",
"    </a>",
"    below.) In a study of data from a United States Department of Agriculture (USDA) Survey of Food Intakes by Individuals, caffeine was consumed by 89 percent of women aged 18 to 34 years and their average intake was 164 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/4\">",
"     4",
"    </a>",
"    ]. In a study from the United Kingdom, the average daily caffeine intake of women of childbearing age was estimated to be 174 mg per day, with up to 18 percent consuming more than 300 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/5\">",
"     5",
"    </a>",
"    ]. A study from Japan reported the mean caffeine intake of women aged 30 to 39 years was 213",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and 7 percent consumed more than 400",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although most women reduce their caffeine intake during pregnancy, in part because of nausea, pregnant women have been reported to consume an average of 60 to 125 mg of caffeine per day [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/4,7\">",
"     4,7",
"    </a>",
"    ], and 10 to 15 percent consumed more than 160 to 200 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS, METABOLISM, AND PHYSIOLOGIC EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     General population",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caffeine (methylated xanthine 1,3,7-trimethylxantine) is a highly soluble compound that readily crosses cell membranes throughout the body. It is rapidly absorbed in the stomach and small intestine and can be detected in human tissues 30 to 45 minutes after ingestion, with peak blood concentration reached within two hours. Clearance values are 1 to 3",
"    <span class=\"nowrap\">",
"     mL/kg/min",
"    </span>",
"    in both men and women after low caffeine intake; however, clearance is diminished with higher doses, largely because of saturable metabolism of caffeine metabolites that accumulate in plasma and reduce caffeine clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/9\">",
"     9",
"    </a>",
"    ]. The volume of distribution of caffeine is 0.7 to 1.3",
"    <span class=\"nowrap\">",
"     L/kg",
"    </span>",
"    and elimination half life is 4.1 to 6.4 hours.",
"   </p>",
"   <p>",
"    Caffeine is metabolized in the liver by the cytochrome P450 family. Cytochrome P450 1A2 (CYP 1A2) is the predominant isoform, accounting for 95 percent of primary caffeine metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/10\">",
"     10",
"    </a>",
"    ]. CYP 2E1 and CYP 1B1 may also make a minor contribution to the primary metabolism of caffeine [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary metabolites of caffeine, paraxanthine (1,7 dimethylxanthine),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    (1,3 dimethylxanthine) and theobromine (3,7 dimethylxanthine), share many of the biological activities of caffeine and also occur independently in natural products [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/9\">",
"     9",
"    </a>",
"    ]. Paraxanthine is the main metabolite in humans and is present in coffee beans; theophylline is a significant xanthine in tea leaves; and theobromine, the weakest of xanthines, is present in cacao beans. Metabolism of these metabolites leads to the formation of monomethylxanthines and methyluracils. Caffeine is excreted by the kidneys, mainly in the form of different metabolites; only 5 to 10 percent is excreted unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caffeine metabolism depends on numerous genetic and environmental factors. Individuals can be classified as slow or fast metabolizers. The factors influencing caffeine metabolism primarily affect CYP 1A2 activity and include cigarette smoking, pregnancy, oral contraceptive use, liver disease, certain medications, genetic polymorphism of CYP 1A2, and ethnicity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, smoking accelerates caffeine metabolism and almost doubles its clearance rate via induction of hepatic oxidative enzymes; this results in a two- to three-fold lower median plasma caffeine concentration in smokers than in non-smokers at the same level of caffeine intake [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/12\">",
"     12",
"    </a>",
"    ]. CYP 1A2 activity is higher in adult males than in females; therefore, females, particularly non-smokers, are prone to more prolonged exposure to caffeine.",
"   </p>",
"   <p>",
"    Caffeine is a stimulant and is commonly used to enhance mental alertness; however, it has a wide range of physiological effects. Chronic use is often associated with habituation and tolerance, while discontinuation may produce withdrawal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/1,9,11\">",
"     1,9,11",
"    </a>",
"    ]. The physiological effects of caffeine in adults are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17498?source=see_link\">",
"     \"Benefits and risks of caffeine and caffeinated beverages\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38375?source=see_link\">",
"     \"Cardiovascular effects of caffeine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Maternal and fetal kinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caffeine and its metabolites readily cross the placenta and can be found in substantial quantities in the amniotic fluid and fetal blood [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Maternal caffeine metabolism declines significantly during pregnancy; the half life increases three-fold in the third trimester, reaching a",
"    <span class=\"nowrap\">",
"     t",
"     <sub>",
"      1/2",
"     </sub>",
"    </span>",
"    of 11.5 to 18 hours. The fetus metabolizes caffeine very slowly, mainly due to immaturity of caffeine-metabolizing hepatic microsome enzymes and lack of CYP 1A2 activity in the placenta. Therefore, even low maternal caffeine consumption can be expected to lead to prolonged fetal caffeine exposure, particularly when the mother is a genetically slow caffeine metabolizer. Infants of smokers have lower umbilical cord blood caffeine concentrations and higher concentrations of caffeine metabolites than infants of non-smokers, reflecting faster caffeine metabolism in smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     QUALITY OF EXISTING EVIDENCE AND METHODOLOGICAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examining the association between caffeine consumption and adverse reproductive outcomes presents a considerable challenge. The consistency and quality of available data have generally been poor. Most studies have methodological shortcomings and were based on epidemiologic research designs usually classified as level III or low quality evidence (ie, comparative studies with concurrent controls but allocation not randomized, cohort studies, case-control studies, or interrupted time series with a control group) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/15\">",
"     15",
"    </a>",
"    ]. A 2013 Cochrane systemic review on the effects of restricted maternal caffeine intake on pregnancy outcomes concluded there was insufficient evidence to confirm or refute the effect of caffeine avoidance on pregnancy outcomes and neonatal health [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are many potential reasons for inconsistent outcomes among studies, including but not limited to [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inaccurate estimation of caffeine consumption",
"     </li>",
"     <li>",
"      Recall bias due to retrospective assessment of caffeine intake",
"     </li>",
"     <li>",
"      Failure to allow for individual variations in caffeine metabolism",
"     </li>",
"     <li>",
"      Inadequate control of confounding factors",
"     </li>",
"     <li>",
"      Selection bias",
"     </li>",
"     <li>",
"      Chemicals other than caffeine in dietary products, which may contribute to the observed outcome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Comprehensive reviews of these methodologic issues are available elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/1,17,18\">",
"     1,17,18",
"    </a>",
"    ], and will be reviewed briefly here. In particular, caffeine consumption is likely to be lower in early than late pregnancy because of early pregnancy nausea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/19\">",
"     19",
"    </a>",
"    ]. The majority of existent studies primarily capture the short-term effects of caffeine by assessing consumption in the period shortly before the studied reproductive event or in individual trimesters rather than throughout pregnancy, although many health-related conditions are likely to have multifactorial causes and a long natural history. It has been difficult to document the long-term effects of caffeine because many new caffeinated products appear in the marketplace and consumption patterns change as a result of dietary advice from a variety of experts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Assessment of caffeine intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of caffeine consumption is methodologically challenging due, in part, to the wide variation of caffeine content in beverages and large differences in serving sizes. The amount of caffeine varies according to source (coffee, tea, chocolate, soft drink), portion size (eg, cup size), brewing method (for coffee and tea), and brand [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/11\">",
"     11",
"    </a>",
"    ]. A standard cup of coffee is often assumed to provide 100 mg of caffeine; however, an analysis of caffeine content of different coffees from various coffee shops revealed variations of 72 to 130",
"    <span class=\"nowrap\">",
"     mg/cup",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/20\">",
"     20",
"    </a>",
"    ]. For espresso, an analysis of caffeine content reported caffeine content of 200 to 322",
"    <span class=\"nowrap\">",
"     mg/cup",
"    </span>",
"    in 20 commercially available espresso products [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coffee is reported as the only source of caffeine in 19 percent of pregnant caffeine consumers, with 26 percent of caffeine intake solely from other non-coffee dietary sources [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Therefore, using coffee consumption as a proxy for caffeine intake leads to gross underestimation of caffeine consumption. The majority of studies on caffeine and reproductive outcomes neither made a comprehensive analysis of intake of all food, drinks, and drugs containing caffeine, nor carefully accounted for the variation of caffeine content from individual portion size, brand, or preparation method of these foods and drinks.",
"   </p>",
"   <p>",
"    Furthermore, most epidemiological studies have relied on self-reported intake of caffeine instead of laboratory assessment of biomarkers. The biomarkers of caffeine exposure (caffeine and its metabolites in blood, urine, and saliva) are of limited use in large population samples, are highly dependent on the timing of the last caffeine intake, and primarily indicate recent consumption rather than long-term exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/8,24\">",
"     8,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although caffeine is detectable in amniotic fluid and in the nails of exposed newborns, studies have not used these types of assays to monitor in utero caffeine exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Recall bias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recall bias refers to differential recall between cases and controls and is of concern because it distorts the internal validity of studies using self-reported data. It affects studies (both retrospective and prospective) in which assessment of caffeine consumption is determined after, rather than before, the occurrence of the health outcome of interest. Patients who have had an adverse event may be more likely to remember perceived unhealthy habits and associate their consumption of coffee with the adverse event, and thus may overestimate their past caffeine consumption compared with patients who have not experienced an adverse event.",
"   </p>",
"   <p>",
"    The importance of recall bias was highlighted by a study that found the correlation between modest caffeine consumption and pregnancy loss disappeared when pregnant women were interviewed about caffeine consumption before, rather than after, they had miscarried [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Individual variations in caffeine metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clearance rate of caffeine varies among individuals and depends on factors affecting cytochrome P450 enzymes, particularly genetic polymorphisms; smoking; and exposure to other compounds that are metabolized by the same enzyme. As a result, despite equivalent caffeine intake, slow metabolizers have higher caffeine concentrations and may be at higher caffeine-related risk than fast metabolizers [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Potential confounders of caffeine consumption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heavy coffee consumption tends to be strongly associated with increased age, cigarette smoking, alcohol consumption, a less health conscious lifestyle, and lower educational level and household income [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/3\">",
"     3",
"    </a>",
"    ]. Other potential confounders include ethnicity, stress, and sleeping pattern. Trying to establish the independent health effects of coffee consumption by adjusting for these potential confounders is difficult and can be inaccurate since their assessment is also affected by measurement error.",
"   </p>",
"   <p>",
"    Nausea and other symptoms of a viable early pregnancy are sometimes called the &ldquo;pregnancy signal.&rdquo; A particular concern in studies of the effects of caffeine intake during pregnancy is that pregnancy related nausea is common and an important confounding factor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/28\">",
"     28",
"    </a>",
"    ]. Nausea in early pregnancy tends to cause dietary changes, such as an aversion to coffee, but is also strongly predictive of fetal survival, presumably because nausea reflects hormonal changes that support continued pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/29\">",
"     29",
"    </a>",
"    ]. For this reason, there has been a concern that the lower caffeine consumption and more favorable pregnancy prognosis among women with nausea compared with those who do not have nausea result in an artificial positive association between low caffeine consumption and better pregnancy outcome. Well-designed studies of caffeine intake and pregnancy outcome attempt to control for the presence or absence of pregnancy signal symptoms in their subjects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Selection bias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the studies on the effect of caffeine on reproductive adversity are based on data obtained from preconception counseling and prenatal health services. The patients attending these services are likely to be more health conscious, which may be associated with lower coffee consumption and thus lead to selection bias, but this would also tend to reduce the associated odds ratios.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other components of caffeinated beverages that may contribute to health effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coffee, tea, and cocoa products contain hundreds of compounds other than caffeine that may contribute to the observed health effects of caffeine consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, coffee and black tea are often consumed with a creamer. Non-dairy creamers contain partially hydrogenated oils that, when used in large amounts, could be a significant dietary source of trans fatty acids, which may have independent adverse effects on reproduction. Trans fatty acids may interfere with the desaturation and elongation of n-3 (omega-3) fatty acids. These are important for the prevention of heart disease and possibly some complications of pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=see_link&amp;anchor=H10#H10\">",
"     \"Nutrition in pregnancy\", section on 'Macronutrients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EFFECTS OF CAFFEINE ON REPRODUCTIVE OUTCOMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10028135\">",
"    <span class=\"h2\">",
"     Animal and in vitro studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in animals can overcome many of the methodological limitations of studies in humans, but pose additional methodological issues that prevent extrapolation to humans. First, humans are highly unlikely to consume the high doses of caffeine used in animal studies. Second, although many metabolic and pharmacokinetic factors related to caffeine are similar in humans and animals, there is not a direct correlation between teratogenic effects in animals and in humans, and the",
"    <span class=\"nowrap\">",
"     dose/anomaly",
"    </span>",
"    relationship may vary between the species. Finally, in some animal studies, caffeine intake is by intravenous or intraperitoneal infusion or gavage feeding, rather than by oral consumption in",
"    <span class=\"nowrap\">",
"     food/drink",
"    </span>",
"    over the course of a day, as in humans. This difference may result in different effects in laboratory animals versus humans. Indeed, when animals receive caffeine doses typically consumed by humans, caffeine is not mutagenic, oncogenic, or cytotoxic [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/17\">",
"     17",
"    </a>",
"    ]. However, it is possible that subteratogenic doses of caffeine may have synergistic detrimental effects with other therapeutic agents consumed by pregnant women.",
"   </p>",
"   <p>",
"    Some examples of findings from animal studies are summarized below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In rodents, a teratogenic effect was demonstrated at high caffeine doses (100 to 330",
"      <span class=\"nowrap\">",
"       mg/kg);",
"      </span>",
"      limb deficiencies, cleft palate, and neural tube defects (NTDs) were among the most frequently observed caffeine-induced congenital malformations [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/31-34\">",
"       31-34",
"      </a>",
"      ]. The caffeine-induced NTD phenotype has been demonstrated by others in various animal models [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/35-38\">",
"       35-38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Caffeine injected into chicken eggs affected monoamine neurotransmitter synthesis in chick embryos and was not metabolized in embryonic brains, which led to caffeine accumulation and magnification of the adverse effects [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/35\">",
"       35",
"      </a>",
"      ]. These changes have been implicated in subsequent neurobehavioral or neurophysiologic deficiencies [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/39-41\">",
"       39-41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rodents given a large bolus or parenteral dose of caffeine are at increased risk of growth restriction in pups; however, no effect on birth weight has been observed when large doses of caffeine were consumed over the course of the day in drinking water [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/17\">",
"       17",
"      </a>",
"      ]. Caffeine boluses also delayed conception and decreased placental weight and gain in maternal bodyweight; these effects were dose dependent [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/42\">",
"       42",
"      </a>",
"      ]. Using a dose-conversion correlation between humans and rats, the lowest dose of caffeine given to pregnant rats and associated with the above effects appeared to be equivalent to 3.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in humans, which is equivalent to consumption of 1.5 to 2.2 cups of coffee by a 70 kg woman.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several basic research studies have assessed the effect of caffeine on trophoblast biology in vitro and suggested molecular mechanisms for deleterious caffeine effect on pregnancy outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. A detailed discussion of these mechanisms is beyond the scope of this topic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10028430\">",
"    <span class=\"h2\">",
"     Human studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the effects of caffeine in humans are largely obtained through epidemiological studies. The bulk of available evidence is low quality and suggests that mild to moderate caffeine intake is not associated with any adverse reproductive outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Even a high level of caffeine intake is not always harmful. In a unique case report, a pregnant woman who consumed a minimum of 5 to 6 cups of coffee per day and often as much as 24 cups of coffee per day delivered an infant without congenital anomalies or growth restriction, but preterm [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3824626\">",
"    <span class=\"h3\">",
"     Physiological effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiological effects of caffeine exposure have not been studied extensively in human pregnancy. Higher maternal plasma caffeine levels appear to be associated with a longer duration of fetal arousal, but fetal tolerance to caffeine exposure also appears to occur [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Other fetal effects possibly related to maternal caffeine consumption include increased fetal heart rate variability, lower basal heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/47,50\">",
"     47,50",
"    </a>",
"    ], and increased fetal breathing activity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. An increase in beat to beat variability and accelerations of the fetal heart rate following maternal intake of even one cup of espresso coffee (60 mg caffeine) or 30 g of &ldquo;dark&rdquo; chocolate (70 percent cocoa) in the third trimester has been attributed to the pharmacological action of theobromine, present in coffee and in chocolate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caffeine consumption may increase release of circulating catecholamines [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/52,53\">",
"     52,53",
"    </a>",
"    ], which could cause uteroplacental vasoconstriction leading to fetal hypoxia, but an increase in catecholamines has not been reported consistently [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/54\">",
"     54",
"    </a>",
"    ]. Increases in maternal homocysteine, cholesterol, and cellular c-AMP concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/55-59\">",
"     55-59",
"    </a>",
"    ] and changes in maternal reproductive hormone levels [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/60\">",
"     60",
"    </a>",
"    ] have also been reported, and potential adverse effects on pregnancy outcome have been hypothesized, but not been proven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Fecundability",
"    </span>",
"    &nbsp;&mdash;&nbsp;When adequately adjusted for other lifestyle factors related to fertility, particularly maternal age, cigarette smoking, and alcohol intake, the bulk of evidence does not support a clear detrimental effect of caffeine on fecundability (ie, probability of conception within a non-contracepting menstrual cycle) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/18,61,62\">",
"     18,61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1988, a study of couples who failed to conceive within the first three months of trying to conceive observed that consumption of at least one cup of coffee, two cups of tea, or 2.5 glasses of cola daily was associated with a marked reduction in fecundability in subsequent cycles compared to women who consumed less caffeine, and a dose response effect was noted [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/63\">",
"     63",
"    </a>",
"    ]. This study prompted further investigation of a possible relationship between caffeine and subfertility. Although some retrospective studies have also observed reduced fecundability, particularly with high caffeine intake [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/64,65\">",
"     64,65",
"    </a>",
"    ], most prospective epidemiological studies have not found a statistically significant association between caffeine consumption and fecundability [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/66-71\">",
"     66-71",
"    </a>",
"    ]. One of these studies was particularly strong because it was the first to use daily, prospective information on caffeine intake and prospectively ascertained pregnancies, including subclinical pregnancies, while controlling for frequency of&nbsp;intercourse, smoking, age, body mass index, frequency of unprotected intercourse, and alcohol intake [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/67\">",
"     67",
"    </a>",
"    ]. Another observed decreased fecundability among women who consumed sodas and increased fecundability among women who drank tea [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/71\">",
"     71",
"    </a>",
"    ]. This indicates that a caffeine exposure variable that does not take into account the specific source may not be appropriate and suggests that these associations may reflect unmeasured confounding by diet or other lifestyle factors.",
"   </p>",
"   <p>",
"    The relationship between caffeine consumption and success of in vitro fertilization (IVF) has not been studied as extensively. In one study, recent caffeine intake by women undergoing IVF did not affect rates of oocyte retrieval, fertilization, embryo transfer, or pregnancy, but more remote caffeine intake seemed to have a negative effect on achieving and maintaining pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/72\">",
"     72",
"    </a>",
"    ]; this was a small study and the confidence intervals around the point estimates were wide. Another study concluded caffeine consumption did not affect overall IVF pregnancy rates; however, higher",
"    <span class=\"nowrap\">",
"     coffee/tea",
"    </span>",
"    consumption was negatively associated with the number of eggs retrieved and the number of good quality embryos [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/73\">",
"     73",
"    </a>",
"    ]. Caffeine was detected in follicular fluid; its actions there are unknown.",
"   </p>",
"   <p>",
"    The available data are not definitive; therefore, reproductive endocrinologists suggest that it may be prudent for women who are having difficulty conceiving to limit caffeine consumption to less than 200 to 300 mg per day, in addition to eliminating tobacco use and decreasing alcohol consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/61,62,74,75\">",
"     61,62,74,75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caffeine consumption by the male partner does not appear to affect male fertility potential [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/65,76-79\">",
"     65,76-79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Spontaneous abortion",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2011 systematic review of both human and animal studies of the risk of spontaneous abortion from caffeine exposure concluded there was fair to good evidence that consumption of caffeinated beverages during pregnancy at a level &le;5 to 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body",
"    <span class=\"nowrap\">",
"     weight/day",
"    </span>",
"    does not increase the risk of spontaneous abortion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/17\">",
"     17",
"    </a>",
"    ]. Although very, very high caffeine intake in some animal studies increased the risk minimally, even a woman who consumed 10 cups of coffee over a period of 8 to 10 hours (approximately 1000 mg of caffeine) would not reach this harmful level of intake.",
"   </p>",
"   <p>",
"    Findings among the 17 epidemiologic studies in this review were inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/17\">",
"     17",
"    </a>",
"    ]. Many studies did not observe an association at any level of reported exposure. Studies that noted a link between caffeine intake and spontaneous abortion generally reported a dose-response relationship, but differed in their conclusions about a threshold for a safe amount of caffeine consumption. In studies that relied upon self-reported caffeine intake, an increased risk of spontaneous abortion generally was not observed until intake levels were &ge;3 cups or &ge;300 mg caffeine per day. By comparison, a study using an objective assessment of caffeine exposure, serum paraxanthine concentration, observed an increased risk beginning at caffeine doses &ge;600 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/80\">",
"     80",
"    </a>",
"    ]. In addition, an analysis within the Danish national birth cohort, which included 565 women who periconceptionally consumed a prescription diet drug (Letigen) containing 200 mg of caffeine per pill, ie, about 600",
"    <span class=\"nowrap\">",
"     mg/treatment",
"    </span>",
"    day, found no association between miscarriage and high dose periconceptional caffeine exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The methodological issues and limitations previously discussed apply to the association reported in these studies, and include confounding by the inverse relationship between maternal nausea and both coffee consumption and miscarriage rate; recall bias; and imprecise ascertainment of caffeine intake [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/25,29\">",
"     25,29",
"    </a>",
"    ]. Other potentially distorting factors include using controls that were not well-matched for gestational age to the study population, lack of ascertainment of the multiple known causes of abortion, a tendency of women to report induced terminations as spontaneous abortions, and inadequate adjustment for multiple known confounders [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1287057\">",
"    <span class=\"h3\">",
"     Congenital anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analysis of data from the National Birth Defects Prevention Study (NBDPS) suggested that maternal dietary caffeine consumption was associated with a slightly increased risk of congenital limb defects (OR 1.4-1.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/82\">",
"     82",
"    </a>",
"    ], NTDs (OR 1.1-1.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/83\">",
"     83",
"    </a>",
"    ], as well as",
"    <span class=\"nowrap\">",
"     anotia/microtia,",
"    </span>",
"    esophageal atresia, small intestinal atresia, and craniosynostosis (OR 1.3&ndash;1.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/84\">",
"     84",
"    </a>",
"    ]. The increased risk was observed with even small amounts of caffeine consumption (above 10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and did not appear to be dose-dependent. The highest caffeine intake (above 300",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was associated with anorectal atresia (OR 1.5, 95% CI 1.0-2.2) and remained unchanged after adjustment for covariates [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/85\">",
"     85",
"    </a>",
"    ]. There was no evidence of an increased risk of cardiovascular malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/86\">",
"     86",
"    </a>",
"    ], orofacial clefts [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/87\">",
"     87",
"    </a>",
"    ], bilateral renal agenesis or hypoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/88\">",
"     88",
"    </a>",
"    ], diaphragmatic hernia, omphalocele, and gastroschisis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although some of these epidemiologic studies reported an association between caffeine intake and certain congenital anomalies, the results should be interpreted with caution due to the methodological flaws of these studies (eg, lack of correction for multiple comparisons, poor ascertainment of caffeine intake, etiologic heterogeneity for some malformations, biased exposure data, biased ascertainment of congenital anomalies) or because the findings were inconsistent with basic teratological principles (eg, lack of dose effect, lack of increasing risk with increasing exposure, lack of consistent association with a specific defect or constellation of defects). Several narrative reviews and a systematic review concluded that caffeine is unlikely to cause congenital anomalies at doses consumed by humans (eg, fractional doses totaling &lt;5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body",
"    <span class=\"nowrap\">",
"     weight/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/17,18,89,90\">",
"     17,18,89,90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Fetal growth restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the relationship between caffeine consumption in pregnancy and fetal growth requires further clarification, a 2011 systematic review concluded it is unlikely that caffeine intake &lt;300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    has a significant adverse effect on fetal growth in non-smoking women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results of epidemiological studies examining the effect of maternal caffeine consumption on the risk of low birth weight (less than 2500 grams) or fetal growth restriction (less than the 10th percentile of birth weight for gestational age) are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/17\">",
"     17",
"    </a>",
"    ]. Several studies observed that maternal caffeine intake ranging from 200 to 400 mg per day was associated with a mean decrease in birth weight of about 100 grams [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/91-93\">",
"     91-93",
"    </a>",
"    ], while other studies either were not able to show any significant association with birth weight or demonstrated reduction in mean birth weight only at caffeine intake exceeding 600 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/94-98\">",
"     94-98",
"    </a>",
"    ]. Many of the available epidemiologic studies have been criticized for inadequately controlling for important risk factors for low birth weight, particularly smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/18,74,89\">",
"     18,74,89",
"    </a>",
"    ]. The following studies exemplify research in this area:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One well-designed large prospective study assessed caffeine consumption from all known sources, objectively quantified intake, and adjusted for smoking and alcohol use [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/23\">",
"       23",
"      </a>",
"      ]. This study included 2635 women in whom caffeine consumption was assessed using a detailed questionnaire and was validated throughout pregnancy by repeated objective measures using saliva samples. Mean caffeine consumption &gt;200",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      over the course of pregnancy was associated with reduction in birth weight of 60 to 70 grams. The risk of fetal growth restriction increased linearly in a dose-response relationship, yielding odds ratios of 1.2 to 1.5 compared to women who consumed less than 100 mg caffeine per day. Although statistically significant, the small differences in birth weight observed in this study are not clinically important. In all trimesters, active smokers had nearly twice the risk of fetal growth restriction compared to non-smokers.",
"     </li>",
"     <li>",
"      A population-based prospective cohort study from the Netherlands including 7346 women reported a statistical trend between increasing caffeine intake and the risk of delivering a small-for-gestational-age (SGA) neonate [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/99\">",
"       99",
"      </a>",
"      ]. Compared with mothers who consumed fewer than two cups of coffee per day, the adjusted odds ratios (OR) for mothers who consumed two to three, four to five, and six or more cups of coffee per day were 1.38, 1.50, and 1.87, (p-value trend &lt;0.01). However, the adjusted OR of delivering an SGA infant did not achieve statistical significance at any level of caffeine intake. Impaired fetal growth was mainly associated with fetal length measures with no significant effect on other parameters, suggesting that high caffeine intake in pregnancy may predominantly affect fetal skeletal growth; this observation requires additional research for confirmation.",
"     </li>",
"     <li>",
"      The only randomized double blind trial that analyzed the effect of reducing caffeine intake on birth weight and length of gestation found that reducing caffeine intake by greater than 50 percent had no significant effect on these outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/100\">",
"       100",
"      </a>",
"      ]. In this trial, 1207 pregnant women who drank at least three cups of coffee per day were randomly assigned to receive unmarked jars of caffeinated or decaffeinated instant coffee for consumption after 20 weeks of gestation. Mean caffeine intake in the decaffeinated and caffeinated coffee groups was 117 and 317",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      respectively. Mean birth weight and mean length of gestation were similar for women in the decaffeinated and caffeinated coffee groups (mean birth weight 3519 versus 3539 grams; mean length of gestation 279.3 versus 280.2 days). However, among women who smoked more than 10 cigarettes a day at study entry, those in the caffeinated coffee group delivered infants 263 grams lower mean birthweight than those in the decaffeinated coffee group.",
"     </li>",
"     <li>",
"      A prospective, longitudinal observational study assessed the relationship between nausea, maternal caffeine intake, caffeine metabolism, and fetal growth restriction in a cohort of 2643 pregnant women recruited in the first trimester [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/101\">",
"       101",
"      </a>",
"      ]. A validated caffeine assessment tool (CAT) was implemented to record habitual caffeine intake, a caffeine challenge test was used to assess a caffeine half-life, and the data were adjusted for smoking and alcohol intake. There was no evidence that nausea and vomiting modified associations between fetal growth restriction and maternal caffeine intake or metabolism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1287261\">",
"    <span class=\"h3\">",
"     Preterm delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review and meta-analysis that combined 15 cohort and 7 case-control studies did not find a significant association between maternal caffeine intake anytime in pregnancy and preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/102\">",
"     102",
"    </a>",
"    ]. The lack of association was observed when comparing &lsquo;any&rsquo; versus &lsquo;no&rsquo; caffeine consumption and for &lsquo;high&rsquo; versus",
"    <span class=\"nowrap\">",
"     &lsquo;low/no&rsquo;",
"    </span>",
"    caffeine consumption. For the highest versus the lowest level of caffeine intake (or no intake) during the first, second, and third trimesters, the odds ratios for preterm birth in cohort studies were 1.11 (95% CI 0.96-1.28), 1.10 (95% CI 1.01-1.19), and 1.08 (95% CI 0.93-1.27), respectively. For case-control studies, the odds ratios were 1.07 (95% CI 0.84-1.37), 1.17 (95% CI 0.94-1.45), and 0.94 (95% CI 0.79-1.12), respectively. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Fetal death",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of observational studies that examined the association between any source of exposure to caffeine from food in pregnancy and fetal mortality concluded that \"the small number of publications, methodological limitations, inaccurate exposure assessment in all the studies, overall risks only marginally significant in most cases, and the possibility of publication bias preclude stating with certainty that caffeine consumption is actually associated with fetal death\" [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Gestational diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a prospective cohort study, preconceptional moderate caffeine intake from coffee appeared to protect against development of gestational diabetes mellitus (GDM) (adjusted RR 0.50; 95% CI 0.29-0.85); there was no risk reduction associated with consumption of decaffeinated coffee or caffeinated tea or soda [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/104\">",
"     104",
"    </a>",
"    ]. These results are consistent with results from epidemiological studies of coffee consumption and risk of type 2 diabetes mellitus, which show that long-term coffee consumption is associated with reduced risk of diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17498?source=see_link&amp;anchor=H15#H15\">",
"     \"Benefits and risks of caffeine and caffeinated beverages\", section on 'Type 2 diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Paradoxically, several studies have shown that exposure to caffeine in experimental settings mildly reduced insulin sensitivity in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/105-107\">",
"     105-107",
"    </a>",
"    ]. This may be due to combination of an indirect effect of caffeine via increasing levels of circulating epinephrine or to direct antagonism of adenosine receptors. Overall, the effect of caffeine on insulin resistance appears to be mild and has been mainly related to acute exposure. Moreover, the researchers in these studies predominantly implemented alkaloid caffeine, which may cause a different physiological response than caffeine from dietary sources. The significance of caffeine&rsquo;s acute effect on the physiological release of insulin in the natural setting, as well as the degree of tolerance to its metabolic effects during chronic consumption, remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/108\">",
"     108",
"    </a>",
"    ]. Pregnant women in whom there are physiological changes in glucose metabolism and a pregnancy-induced state of peripheral insulin resistance may be more likely to show the acute effects of caffeine observed in experimental settings. A retrospective study on banked blood samples of 251 women in the second trimester (mean gestational age of 20.3 weeks) showed a positive association between the risk of insulin resistance (estimated by homeostasis model assessment) and higher levels of caffeine and its metabolite paraxanthine in the blood [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/109\">",
"     109",
"    </a>",
"    ]. Caffeine concentrations &gt;266",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and paraxanthine concentrations &gt;392",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    were associated with three-fold higher odds of having higher insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/109\">",
"     109",
"    </a>",
"    ]. The clinical significance of these findings was not studied and requires further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12988003\">",
"    <span class=\"h3\">",
"     Gestational hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;A group from the Netherlands assessed the effect of caffeine consumption on maternal cardiovascular changes in a cohort of 7890 pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/110\">",
"     110",
"    </a>",
"    ]. Although higher caffeine intake was associated with elevated systolic blood pressure in the first and third trimesters, there was no effect on diastolic blood pressure levels and caffeine consumption appeared to be protective against preeclampsia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10028798\">",
"    <span class=\"h3\">",
"     Postpartum depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A study of 662 women recruited within 24 hours of giving birth did not observe an association between prenatal caffeine intake and depressive symptoms postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Long-term health consequences of intrauterine exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Associations between in utero caffeine exposure and attention deficit disorder, cognitive development, behavioral problems, leukemia, testicular cancer, and sudden infant death syndrome in offspring have been evaluated, but the available data are inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/3,112-120\">",
"     3,112-120",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     LACTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Pediatrics (AAP) categorizes caffeine as a medication usually compatible with breastfeeding, but recommends that lactating women consume no more than 200 to 300 mg of caffeine per day [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/121\">",
"     121",
"    </a>",
"    ]. A lower intake is suggested for mothers of preterm infants and newborns since they metabolize caffeine very slowly.",
"   </p>",
"   <p>",
"    Caffeine is detectable in breast milk within 15 minutes of consumption and levels peak after about one hour. Maternal caffeine consumption of 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    results in daily infant caffeine intake ranging from 0.3 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight and caffeine levels 1 percent of maternal levels [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/74\">",
"     74",
"    </a>",
"    ]. Adverse effects have not been reported in term infants whose mothers had moderate intake of up to five cups of coffee daily [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/122\">",
"     122",
"    </a>",
"    ], but some case reports have described an increase in infant irritability, jitteriness, or sleep disturbance at this level of maternal caffeine consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/123,124\">",
"     123,124",
"    </a>",
"    ]. In one of the larger series (n = 885 infants), heavy (&ge;300",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    maternal caffeine consumption during pregnancy and three months postpartum by breastfeeding mothers was associated with an increase in the percentage of infants with frequent (&gt;3 times per night) nocturnal wakening (19.5 versus 13.3 percent with non-heavy or no maternal caffeine consumption; RR 1.65, 95% CI 0.86-3.17), but the difference was not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/125\">",
"     125",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=see_link&amp;anchor=H25#H25\">",
"     \"Principles of medication use during lactation\", section on 'Social substances'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF SOCIETIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;No uniform counseling guidelines or evidence-based recommendations for caffeine intake are available.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The March of Dimes recommends that women who are pregnant or trying to become pregnant consume no more than 200 mg of caffeine per day [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/126\">",
"       126",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Health Canada suggests daily caffeine intake of no more than 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in women who are planning to become pregnant, pregnant women, and breastfeeding mothers [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/127\">",
"       127",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The United Kingdom Food Standards Agency (FSA) does not provide any guidelines on caffeine consumption in the general population, but suggests limiting caffeine intake in pregnancy to 200 mg per day [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/128\">",
"       128",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A Committee Opinion by the American College of Obstetricians and Gynecologists (ACOG) concluded that moderate caffeine consumption (&lt;200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      did not appear to be a contributing factor to miscarriage or preterm birth, and the relationship with fetal growth restriction was unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/129\">",
"       129",
"      </a>",
"      ]. Specific recommendations about caffeine intake in pregnancy were not provided.",
"     </li>",
"     <li>",
"      The American Dietetic Association (ADA) recommends that pregnant women avoid caffeine intakes above 300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?19/35/20026/abstract/130\">",
"       130",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In many countries, the main source of caffeine is coffee, followed by tea and caffeinated beverages. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Sources of caffeine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maternal caffeine metabolism declines significantly during pregnancy. Caffeine and its metabolites readily cross the placenta and can be found in substantial quantities in the amniotic fluid and fetal blood. Higher maternal plasma caffeine levels appear to be associated with a longer duration of fetal arousal, increased fetal heart rate variability, lower basal fetal heart rate, increased fetal breathing activity, and inconsistent effects on fetal and placental blood flow. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Maternal and fetal kinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The consistency and quality of available data regarding the effects of caffeine on fertility and pregnancy outcomes have generally been poor. Most studies have methodological shortcomings. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Quality of existing evidence and methodological considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At typical levels of caffeine intake, there does not appear to be an association between caffeine consumption and fecundability or adverse reproductive events, including congenital anomalies, spontaneous abortion, fetal growth restriction, and preterm birth. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Effects of caffeine on reproductive outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preconceptional moderate coffee intake appears to protect against development of gestational diabetes mellitus. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Gestational diabetes mellitus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the limitations and inconsistencies of available data, we suggest women who are attempting to conceive or who are pregnant or breastfeeding limit caffeine consumption to less than 200 to 300 mg per day (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Examples of the caffeine content of various beverages are shown in the table (",
"      <a class=\"graphic graphic_table graphicRef79304 \" href=\"UTD.htm?30/43/31422\">",
"       table 1",
"      </a>",
"      ) and available at",
"      <a class=\"external\" href=\"file://www.cspinet.org/new/cafchart.htm\">",
"       file://www.cspinet.org/new/cafchart.htm",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Recommendations of societies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Quality of existing evidence and methodological considerations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Effects of caffeine on reproductive outcomes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'Lactation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/1\">",
"      Grosso LM, Bracken MB. Caffeine metabolism, genetics, and perinatal outcomes: a review of exposure assessment considerations during pregnancy. Ann Epidemiol 2005; 15:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/2\">",
"      Refsum H, Nurk E, Smith AD, et al. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr 2006; 136:1731S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/3\">",
"      van Dam RM. Coffee consumption and risk of type 2 diabetes, cardiovascular diseases, and cancer. Appl Physiol Nutr Metab 2008; 33:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/4\">",
"      Frary CD, Johnson RK, Wang MQ. Food sources and intakes of caffeine in the diets of persons in the United States. J Am Diet Assoc 2005; 105:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/5\">",
"      Derbyshire E, Abdula S. Habitual caffeine intake in women of childbearing age. J Hum Nutr Diet 2008; 21:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/6\">",
"      Yamada M, Sasaki S, Murakami K, et al. Estimation of caffeine intake in Japanese adults using 16 d weighed diet records based on a food composition database newly developed for Japanese populations. Public Health Nutr 2010; 13:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/7\">",
"      Knight CA, Knight I, Mitchell DC, Zepp JE. Beverage caffeine intake in US consumers and subpopulations of interest: estimates from the Share of Intake Panel survey. Food Chem Toxicol 2004; 42:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/8\">",
"      Boylan SM, Cade JE, Kirk SF, et al. Assessing caffeine exposure in pregnant women. Br J Nutr 2008; 100:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/9\">",
"      Mandel HG. Update on caffeine consumption, disposition and action. Food Chem Toxicol 2002; 40:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/10\">",
"      Andersen MR, Farin FM, Omiecinski CJ. Quantification of multiple human cytochrome P450 mRNA molecules using competitive reverse transcriptase-PCR. DNA Cell Biol 1998; 17:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/11\">",
"      Harland BF. Caffeine and nutrition. Nutrition 2000; 16:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/12\">",
"      de Leon J, Diaz FJ, Rogers T, et al. A pilot study of plasma caffeine concentrations in a US sample of smoker and nonsmoker volunteers. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/13\">",
"      Szucs, G, Myers, VA, Miwa, LJ. Caffeine consumption during pregnancy. Drug Intell Clin Pharm 1988; 22:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/14\">",
"      Berger A. Effects of caffeine consumption on pregnancy outcome. A review. J Reprod Med 1988; 33:945.",
"     </a>",
"    </li>",
"    <li>",
"     National Health and Medical Research Council. A guide to the development, implementation and evaluation of clinical practice guidelines. NHMRC 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/16\">",
"      Jahanfar S, Jaafar SH. Effects of restricted caffeine intake by mother on fetal, neonatal and pregnancy outcome. Cochrane Database Syst Rev 2013; 2:CD006965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/17\">",
"      Brent RL, Christian MS, Diener RM. Evaluation of the reproductive and developmental risks of caffeine. Birth Defects Res B Dev Reprod Toxicol 2011; 92:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/18\">",
"      Peck JD, Leviton A, Cowan LD. A review of the epidemiologic evidence concerning the reproductive health effects of caffeine consumption: a 2000-2009 update. Food Chem Toxicol 2010; 48:2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/19\">",
"      Stein Z, Susser M. Miscarriage, caffeine, and the epiphenomena of pregnancy: the causal model. Epidemiology 1991; 2:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/20\">",
"      McCusker RR, Goldberger BA, Cone EJ. Caffeine content of specialty coffees. J Anal Toxicol 2003; 27:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/21\">",
"      Crozier TW, Stalmach A, Lean ME, Crozier A. Espresso coffees, caffeine and chlorogenic acid intake: potential health implications. Food Funct 2012; 3:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/22\">",
"      Weng X, Odouli R, Li DK. Maternal caffeine consumption during pregnancy and the risk of miscarriage: a prospective cohort study. Am J Obstet Gynecol 2008; 198:279.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/23\">",
"      CARE Study Group. Maternal caffeine intake during pregnancy and risk of fetal growth restriction: a large prospective observational study. BMJ 2008; 337:a2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/24\">",
"      Grosso LM, Triche E, Benowitz NL, Bracken MB. Prenatal caffeine assessment: fetal and maternal biomarkers or self-reported intake? Ann Epidemiol 2008; 18:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/25\">",
"      Savitz DA, Chan RL, Herring AH, et al. Caffeine and miscarriage risk. Epidemiology 2008; 19:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/26\">",
"      Signorello LB, Nordmark A, Granath F, et al. Caffeine metabolism and the risk of spontaneous abortion of normal karyotype fetuses. Obstet Gynecol 2001; 98:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/27\">",
"      Sata F, Yamada H, Suzuki K, et al. Caffeine intake, CYP1A2 polymorphism and the risk of recurrent pregnancy loss. Mol Hum Reprod 2005; 11:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/28\">",
"      Maconochie N, Doyle P, Prior S, Simmons R. Risk factors for first trimester miscarriage--results from a UK-population-based case-control study. BJOG 2007; 114:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/29\">",
"      Furneaux EC, Langley-Evans AJ, Langley-Evans SC. Nausea and vomiting of pregnancy: endocrine basis and contribution to pregnancy outcome. Obstet Gynecol Surv 2001; 56:775.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Agriculture Agricultural Research Service. USDA National Nutrient Database for Standard Reference, release 21. file://www.ars.usda.gov/nutrientdata. (Accessed on July 06, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/31\">",
"      Nehlig A, Debry G. Potential teratogenic and neurodevelopmental consequences of coffee and caffeine exposure: a review on human and animal data. Neurotoxicol Teratol 1994; 16:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/32\">",
"      NISHIMURA H, NAKAI K. Congenital malformations in offspring of mice treated with caffeine. Proc Soc Exp Biol Med 1960; 104:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/33\">",
"      Scott WJ Jr. Caffeine-induced limb malformations: description of malformations and quantitation of placental transfer. Teratology 1983; 28:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/34\">",
"      Moriguchi M, Scott WJ Jr. Prevention of caffeine-induced limb malformations by maternal adrenalectomy. Teratology 1986; 33:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/35\">",
"      Li XD, He RR, Qin Y, et al. Caffeine interferes embryonic development through over-stimulating serotonergic system in chicken embryo. Food Chem Toxicol 2012; 50:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/36\">",
"      Ma ZL, Qin Y, Wang G, et al. Exploring the caffeine-induced teratogenicity on neurodevelopment using early chick embryo. PLoS One 2012; 7:e34278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/37\">",
"      Marret S, Gressens P, Van-Maele-Fabry G, et al. Caffeine-induced disturbances of early neurogenesis in whole mouse embryo cultures. Brain Res 1997; 773:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/38\">",
"      Wilkinson JM, Pollard I. In utero exposure to caffeine causes delayed neural tube closure in rat embryos. Teratog Carcinog Mutagen 1994; 14:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/39\">",
"      Gross C, Zhuang X, Stark K, et al. Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 2002; 416:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/40\">",
"      Herlenius E, Lagercrantz H. Development of neurotransmitter systems during critical periods. Exp Neurol 2004; 190 Suppl 1:S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/41\">",
"      Weinstock M. Does prenatal stress impair coping and regulation of hypothalamic-pituitary-adrenal axis? Neurosci Biobehav Rev 1997; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/42\">",
"      Huang J, Zhou S, Ping J, et al. Role of p53-dependent placental apoptosis in the reproductive and developmental toxicities of caffeine in rodents. Clin Exp Pharmacol Physiol 2012; 39:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/43\">",
"      Sharmin S, Guan H, Williams AS, Yang K. Caffeine reduces 11&beta;-hydroxysteroid dehydrogenase type 2 expression in human trophoblast cells through the adenosine A(2B) receptor. PLoS One 2012; 7:e38082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/44\">",
"      Shams M, Kilby MD, Somerset DA, et al. 11Beta-hydroxysteroid dehydrogenase type 2 in human pregnancy and reduced expression in intrauterine growth restriction. Hum Reprod 1998; 13:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/45\">",
"      Grant I, Cartwright JE, Lumicisi B, et al. Caffeine inhibits EGF-stimulated trophoblast cell motility through the inhibition of mTORC2 and Akt. Endocrinology 2012; 153:4502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/46\">",
"      Khanna NN, Somani SM. Maternal coffee drinking and unusually high concentrations of caffeine in the newborn. J Toxicol Clin Toxicol 1984; 22:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/47\">",
"      Mulder EJ, Tegaldo L, Bruschettini P, Visser GH. Foetal response to maternal coffee intake: role of habitual versus non-habitual caffeine consumption. J Psychopharmacol 2010; 24:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/48\">",
"      Devoe LD, Murray C, Youssif A, Arnaud M. Maternal caffeine consumption and fetal behavior in normal third-trimester pregnancy. Am J Obstet Gynecol 1993; 168:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/49\">",
"      McGowan J, Devoe LD, Searle N, Altman R. The effects of long- and short-term maternal caffeine ingestion on human fetal breathing and body movements in term gestations. Am J Obstet Gynecol 1987; 157:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/50\">",
"      Salvador HS, Koos BJ. Effects of regular and decaffeinated coffee on fetal breathing and heart rate. Am J Obstet Gynecol 1989; 160:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/51\">",
"      Buscicchio G, Piemontese M, Gentilucci L, et al. The effects of maternal caffeine and chocolate intake on fetal heart rate. J Matern Fetal Neonatal Med 2012; 25:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/52\">",
"      Kirkinen P, Jouppila P, Koivula A, et al. The effect of caffeine on placental and fetal blood flow in human pregnancy. Am J Obstet Gynecol 1983; 147:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/53\">",
"      Soyka LF. Effects of methylxanthines on the fetus. Clin Perinatol 1979; 6:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/54\">",
"      Tsubouchi H, Shimoya K, Hayashi S, et al. Effect of coffee intake on blood flow and maternal stress during the third trimester of pregnancy. Int J Gynaecol Obstet 2006; 92:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/55\">",
"      Mills JL, McPartlin JM, Kirke PN, et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995; 345:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/56\">",
"      Wenstrom KD, Johanning GL, Johnston KE, DuBard M. Association of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malformations. Am J Obstet Gynecol 2001; 184:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/57\">",
"      Verhoef P, Pasman WJ, Van Vliet T, et al. Contribution of caffeine to the homocysteine-raising effect of coffee: a randomized controlled trial in humans. Am J Clin Nutr 2002; 76:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/58\">",
"      Liu YA, Ostlund E, Fried G. Endothelin-induced contractions in human placental blood vessels are enhanced in intrauterine growth retardation, and modulated by agents that regulate levels of intracellular calcium. Acta Physiol Scand 1995; 155:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/59\">",
"      Manderson JG, Mullan B, Patterson CC, et al. Cardiovascular and metabolic abnormalities in the offspring of diabetic pregnancy. Diabetologia 2002; 45:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/60\">",
"      Sowers MR, Crawford S, McConnell DS, et al. Selected diet and lifestyle factors are associated with estrogen metabolites in a multiracial/ethnic population of women. J Nutr 2006; 136:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/61\">",
"      Practice Committee of American Society for Reproductive Medicine in collaboration with Society for Reproductive Endocrinology and Infertility. Optimizing natural fertility. Fertil Steril 2008; 90:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/62\">",
"      Homan GF, Davies M, Norman R. The impact of lifestyle factors on reproductive performance in the general population and those undergoing infertility treatment: a review. Hum Reprod Update 2007; 13:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/63\">",
"      Wilcox A, Weinberg C, Baird D. Caffeinated beverages and decreased fertility. Lancet 1988; 2:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/64\">",
"      Bol&uacute;mar F, Olsen J, Rebagliato M, Bisanti L. Caffeine intake and delayed conception: a European multicenter study on infertility and subfecundity. European Study Group on Infertility Subfecundity. Am J Epidemiol 1997; 145:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/65\">",
"      Hassan MA, Killick SR. Negative lifestyle is associated with a significant reduction in fecundity. Fertil Steril 2004; 81:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/66\">",
"      Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC. Caffeinated and alcoholic beverage intake in relation to ovulatory disorder infertility. Epidemiology 2009; 20:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/67\">",
"      Taylor KC, Small CM, Dominguez CE, et al. alcohol, smoking, and caffeine in relation to fecundability, with effect modification by NAT2. Ann Epidemiol 2011; 21:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/68\">",
"      Caan B, Quesenberry CP Jr, Coates AO. Differences in fertility associated with caffeinated beverage consumption. Am J Public Health 1998; 88:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/69\">",
"      Florack EI, Zielhuis GA, Rolland R. Cigarette smoking, alcohol consumption, and caffeine intake and fecundability. Prev Med 1994; 23:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/70\">",
"      Jensen TK, Henriksen TB, Hjollund NH, et al. Caffeine intake and fecundability: a follow-up study among 430 Danish couples planning their first pregnancy. Reprod Toxicol 1998; 12:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/71\">",
"      Hatch EE, Wise LA, Mikkelsen EM, et al. Caffeinated beverage and soda consumption and time to pregnancy. Epidemiology 2012; 23:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/72\">",
"      Klonoff-Cohen H, Bleha J, Lam-Kruglick P. A prospective study of the effects of female and male caffeine consumption on the reproductive endpoints of IVF and gamete intra-Fallopian transfer. Hum Reprod 2002; 17:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/73\">",
"      Al-Saleh I, El-Doush I, Grisellhi B, Coskun S. The effect of caffeine consumption on the success rate of pregnancy as well various performance parameters of in-vitro fertilization treatment. Med Sci Monit 2010; 16:CR598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/74\">",
"      Higdon JV, Frei B. Coffee and health: a review of recent human research. Crit Rev Food Sci Nutr 2006; 46:101.",
"     </a>",
"    </li>",
"    <li>",
"     www.marchofdimes.com/professionals/14332_1148.asp. (Accessed on August 12, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/76\">",
"      Ramlau-Hansen CH, Thulstrup AM, Bonde JP, et al. Semen quality according to prenatal coffee and present caffeine exposure: two decades of follow-up of a pregnancy cohort. Hum Reprod 2008; 23:2799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/77\">",
"      Horak S, Polanska J, Widlak P. Bulky DNA adducts in human sperm: relationship with fertility, semen quality, smoking, and environmental factors. Mutat Res 2003; 537:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/78\">",
"      Sobreiro BP, Lucon AM, Pasqualotto FF, et al. Semen analysis in fertile patients undergoing vasectomy: reference values and variations according to age, length of sexual abstinence, seasonality, smoking habits and caffeine intake. Sao Paulo Med J 2005; 123:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/79\">",
"      Schmid TE, Eskenazi B, Baumgartner A, et al. The effects of male age on sperm DNA damage in healthy non-smokers. Hum Reprod 2007; 22:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/80\">",
"      Klebanoff MA, Levine RJ, DerSimonian R, et al. Maternal serum paraxanthine, a caffeine metabolite, and the risk of spontaneous abortion. N Engl J Med 1999; 341:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/81\">",
"      Howards PP, Hertz-Picciotto I, Bech BH, et al. Spontaneous abortion and a diet drug containing caffeine and ephedrine: a study within the Danish national birth cohort. PLoS One 2012; 7:e50372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/82\">",
"      Chen L, Bell EM, Browne ML, et al. Maternal caffeine consumption and risk of congenital limb deficiencies. Birth Defects Res A Clin Mol Teratol 2012; 94:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/83\">",
"      Schmidt RJ, Romitti PA, Burns TL, et al. Maternal caffeine consumption and risk of neural tube defects. Birth Defects Res A Clin Mol Teratol 2009; 85:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/84\">",
"      Browne ML, Hoyt AT, Feldkamp ML, et al. Maternal caffeine intake and risk of selected birth defects in the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 2011; 91:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/85\">",
"      Miller EA, Manning SE, Rasmussen SA, et al. Maternal exposure to tobacco smoke, alcohol and caffeine, and risk of anorectal atresia: National Birth Defects Prevention Study 1997-2003. Paediatr Perinat Epidemiol 2009; 23:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/86\">",
"      Menke RA, Abraham I, Thiel CS, et al. Fractional Anisotropy in the Posterior Limb of the Internal Capsule and Prognosis in Amyotrophic Lateral Sclerosis. Arch Neurol 2012; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/87\">",
"      Collier SA, Browne ML, Rasmussen SA, et al. Maternal caffeine intake during pregnancy and orofacial clefts. Birth Defects Res A Clin Mol Teratol 2009; 85:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/88\">",
"      Slickers JE, Olshan AF, Siega-Riz AM, et al. Maternal body mass index and lifestyle exposures and the risk of bilateral renal agenesis or hypoplasia: the National Birth Defects Prevention Study. Am J Epidemiol 2008; 168:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/89\">",
"      Nawrot P, Jordan S, Eastwood J, et al. Effects of caffeine on human health. Food Addit Contam 2003; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/90\">",
"      Browne ML. Maternal exposure to caffeine and risk of congenital anomalies: a systematic review. Epidemiology 2006; 17:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/91\">",
"      Martin TR, Bracken MB. The association between low birth weight and caffeine consumption during pregnancy. Am J Epidemiol 1987; 126:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/92\">",
"      Fortier I, Marcoux S, Beaulac-Baillargeon L. Relation of caffeine intake during pregnancy to intrauterine growth retardation and preterm birth. Am J Epidemiol 1993; 137:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/93\">",
"      Fenster L, Eskenazi B, Windham GC, Swan SH. Caffeine consumption during pregnancy and fetal growth. Am J Public Health 1991; 81:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/94\">",
"      Jarosz M, Wierzejska R, Siuba M. Maternal caffeine intake and its effect on pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol 2012; 160:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/95\">",
"      Clausson B, Granath F, Ekbom A, et al. Effect of caffeine exposure during pregnancy on birth weight and gestational age. Am J Epidemiol 2002; 155:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/96\">",
"      Grosso LM, Rosenberg KD, Belanger K, et al. Maternal caffeine intake and intrauterine growth retardation. Epidemiology 2001; 12:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/97\">",
"      Parazzini F, Chiaffarino F, Chatenoud L, et al. Maternal coffee drinking in pregnancy and risk of small for gestational age birth. Eur J Clin Nutr 2005; 59:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/98\">",
"      Santos IS, Matijasevich A, Valle NC. Mate drinking during pregnancy and risk of preterm and small for gestational age birth. J Nutr 2005; 135:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/99\">",
"      Bakker R, Steegers EA, Obradov A, et al. Maternal caffeine intake from coffee and tea, fetal growth, and the risks of adverse birth outcomes: the Generation R Study. Am J Clin Nutr 2010; 91:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/100\">",
"      Bech BH, Obel C, Henriksen TB, Olsen J. Effect of reducing caffeine intake on birth weight and length of gestation: randomised controlled trial. BMJ 2007; 334:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/101\">",
"      Boylan SM, Greenwood DC, Alwan N, et al. Does Nausea and Vomiting of Pregnancy Play a Role in the Association Found Between Maternal Caffeine Intake and Fetal Growth Restriction? Matern Child Health J 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/102\">",
"      Maslova E, Bhattacharya S, Lin SW, Michels KB. Caffeine consumption during pregnancy and risk of preterm birth: a meta-analysis. Am J Clin Nutr 2010; 92:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/103\">",
"      Matijasevich A, Santos IS, Barros FC. Does caffeine consumption during pregnancy increase the risk of fetal mortality? A literature review. Cad Saude Publica 2005; 21:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/104\">",
"      Adeney KL, Williams MA, Schiff MA, et al. Coffee consumption and the risk of gestational diabetes mellitus. Acta Obstet Gynecol Scand 2007; 86:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/105\">",
"      Tunnicliffe JM, Shearer J. Coffee, glucose homeostasis, and insulin resistance: physiological mechanisms and mediators. Appl Physiol Nutr Metab 2008; 33:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/106\">",
"      Beaudoin MS, Graham TE. Methylxanthines and human health: epidemiological and experimental evidence. Handb Exp Pharmacol 2011; :509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/107\">",
"      Robinson LE, Spafford C, Graham TE, Smith GN. Acute caffeine ingestion and glucose tolerance in women with or without gestational diabetes mellitus. J Obstet Gynaecol Can 2009; 31:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/108\">",
"      Biaggioni I, Davis SN. Caffeine: a cause of insulin resistance? Diabetes Care 2002; 25:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/109\">",
"      Laughon SK, Powers RW, Roberts JM, et al. Caffeine and insulin resistance in pregnancy. Am J Perinatol 2011; 28:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/110\">",
"      Bakker R, Steegers EA, Raat H, et al. Maternal caffeine intake, blood pressure, and the risk of hypertensive complications during pregnancy. The Generation R Study. Am J Hypertens 2011; 24:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/111\">",
"      Dagher RK, Shenassa ED. Prenatal health behaviors and postpartum depression: is there an association? Arch Womens Ment Health 2012; 15:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/112\">",
"      Barr HM, Streissguth AP. Caffeine use during pregnancy and child outcome: a 7-year prospective study. Neurotoxicol Teratol 1991; 13:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/113\">",
"      Linnet KM, Wisborg K, Secher NJ, et al. Coffee consumption during pregnancy and the risk of hyperkinetic disorder and ADHD: a prospective cohort study. Acta Paediatr 2009; 98:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/114\">",
"      Williams JH, Ross L. Consequences of prenatal toxin exposure for mental health in children and adolescents: a systematic review. Eur Child Adolesc Psychiatry 2007; 16:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/115\">",
"      Mongraw-Chaffin ML, Cohn BA, Cohen RD, Christianson RE. Maternal smoking, alcohol consumption, and caffeine consumption during pregnancy in relation to a son's risk of persistent cryptorchidism: a prospective study in the Child Health and Development Studies cohort, 1959-1967. Am J Epidemiol 2008; 167:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/116\">",
"      Menegaux F, Ripert M, H&eacute;mon D, Clavel J. Maternal alcohol and coffee drinking, parental smoking and childhood leukaemia: a French population-based case-control study. Paediatr Perinat Epidemiol 2007; 21:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/117\">",
"      Mongraw-Chaffin ML, Cohn BA, Anglemyer AT, et al. Maternal smoking, alcohol, and coffee use during pregnancy and son's risk of testicular cancer. Alcohol 2009; 43:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/118\">",
"      Ford RP, Schluter PJ, Mitchell EA, et al. Heavy caffeine intake in pregnancy and sudden infant death syndrome. New Zealand Cot Death Study Group. Arch Dis Child 1998; 78:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/119\">",
"      Bekkhus M, Skj&oslash;thaug T, Nordhagen R, Borge AI. Intrauterine exposure to caffeine and inattention/overactivity in children. Acta Paediatr 2010; 99:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/120\">",
"      Loomans EM, Hofland L, van der Stelt O, et al. Caffeine intake during pregnancy and risk of problem behavior in 5- to 6-year-old children. Pediatrics 2012; 130:e305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/121\">",
"      American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001; 108:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/122\">",
"      James JJ. Deepwater Horizon drilling rig explosion and the resulting massive oil spill into the Gulf of Mexico. Disaster Med Public Health Prep 2010; 4:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/123\">",
"      Rivera-calimlim L. Drugs in breast milk. Drug Ther (NY) 1977; 7:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/124\">",
"      Caffeine and babies. BMJ 1989; 299:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/125\">",
"      Santos IS, Matijasevich A, Domingues MR. Maternal caffeine consumption and infant nighttime waking: prospective cohort study. Pediatrics 2012; 129:860.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.marchofdimes.com/professionals/25079_1148.asp (Accessed on November 15, 2012).",
"    </li>",
"    <li>",
"     Health Canada. Caffeine in food. February 16, 2012. file://www.hc-sc.gc.ca/fn-an/securit/addit/caf/food-caf-aliments-eng.php (Accessed on October 15, 2012).",
"    </li>",
"    <li>",
"     Food Standards Agency new caffeine advice for pregnant women. file://www.food.gov.uk/news/newsarchive/2008/nov/caffeinenov08. (Accessed on July 06, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/129\">",
"      American College of Obstetricians and Gynecologists. ACOG CommitteeOpinion No. 462: Moderate caffeine consumption during pregnancy. Obstet Gynecol 2010; 116:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/35/20026/abstract/130\">",
"      Kaiser L, Allen LH, American Dietetic Association. Position of the American Dietetic Association: nutrition and lifestyle for a healthy pregnancy outcome. J Am Diet Assoc 2008; 108:553.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 406 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-50E636C042-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_35_20026=[""].join("\n");
var outline_f19_35_20026=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SOURCES OF CAFFEINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CAFFEINE CONSUMPTION IN WOMEN OF REPRODUCTIVE AGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PHARMACOKINETICS, METABOLISM, AND PHYSIOLOGIC EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      General population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Maternal and fetal kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      QUALITY OF EXISTING EVIDENCE AND METHODOLOGICAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Assessment of caffeine intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Recall bias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Individual variations in caffeine metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Potential confounders of caffeine consumption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Selection bias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other components of caffeinated beverages that may contribute to health effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EFFECTS OF CAFFEINE ON REPRODUCTIVE OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10028135\">",
"      Animal and in vitro studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10028430\">",
"      Human studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3824626\">",
"      - Physiological effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Fecundability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Spontaneous abortion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1287057\">",
"      - Congenital anomalies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Fetal growth restriction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1287261\">",
"      - Preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Fetal death",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Gestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12988003\">",
"      - Gestational hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10028798\">",
"      - Postpartum depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Long-term health consequences of intrauterine exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      LACTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      RECOMMENDATIONS OF SOCIETIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/406\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/406|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/43/31422\" title=\"table 1\">",
"      Caffeine content",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/5/17498?source=related_link\">",
"      Benefits and risks of caffeine and caffeinated beverages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38375?source=related_link\">",
"      Cardiovascular effects of caffeine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=related_link\">",
"      Nutrition in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_35_20027="Syndromes fetal macrosomia";
var content_f19_35_20027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genetic syndromes frequently associated with macrosomia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Syndrome",
"       </td>",
"       <td class=\"subtitle1\">",
"        Main characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beckwith-Wiedemann",
"       </td>",
"       <td>",
"        Macroglossia, omphalocele, macrosomia, ear creases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Marshall-Smith",
"       </td>",
"       <td>",
"        Accelerated growth and maturation, shallow orbits, broad middle phalanges",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Simpson-Golabi-Behmel",
"       </td>",
"       <td>",
"        Macrocephaly, coarse face, ocular hypertelorism, broad flat nose, macrostomia, macroglossia, nail hypoplasia, skeletal abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sotos (cerebral gigantism)",
"       </td>",
"       <td>",
"        Large size, large hands and feet, poor coordination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Berardinelli lipodystrophy",
"       </td>",
"       <td>",
"        Lipoatrophy, phallic hypertrophy, hepatomegaly, hyperlipemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weaver",
"       </td>",
"       <td>",
"        Macrosomia, accelerated skeletal maturation, camptodactyly, unusual facies",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Jones KL. Smith's Recognizable Patterns of Human Malformation. WB Saunders, Philadelphia 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_35_20027=[""].join("\n");
var outline_f19_35_20027=null;
var title_f19_35_20028="Features of Mansonella spp II";
var content_f19_35_20028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70668&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Features of mansonella species causing human infection - II",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        M. streptocera",
"       </td>",
"       <td class=\"subtitle1\">",
"        M. ozzardi",
"       </td>",
"       <td class=\"subtitle1\">",
"        M. perstans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Diagnosis",
"       </td>",
"       <td>",
"        Microfilariae (mf)&nbsp;in skin snips. Differentiated from mf&nbsp;of Onchocerca volvulus by small size (180 to 240 micrometers) and characteristic sharp curve in tip of tail (\"shepherd's crook\").",
"       </td>",
"       <td>",
"        Microfilariae (mf) in blood and occasionally in skin snips. Differentiated from other circulating mf by lack of significant periodicity, small size (170 to 240 micrometers long), absence of sheath and absence of terminal nuclei.",
"       </td>",
"       <td>",
"        Microfilariae (mf) in blood (or rarely&nbsp;serosal effusions). Differentiated from other circulating mf by lack of significant periodicity, small size (190 to 200 micrometers), absence of sheath, and round terminal nucleus at the tip of the tail.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Other laboratory findings",
"       </td>",
"       <td>",
"        Peripheral eosinophilia is common.",
"       </td>",
"       <td>",
"        Peripheral eosinophilia is common.",
"       </td>",
"       <td>",
"        Peripheral eosinophilia and elevated serum IgE are common.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Treatment",
"       </td>",
"       <td>",
"        Diethylcarbamazine (6 mg/kg/day&nbsp;orally for 14 days) is effective against adults and microfilariae (mf) but associated with significant side effects. Ivermectin (150 mcg/kg orally) is effective in reducing mf.*",
"       </td>",
"       <td>",
"        Ivermectin (200 mcg/kg orally) is the treatment of choice.",
"        <sup>",
"         &bull;",
"        </sup>",
"        Diethylcarbamazine is ineffective.",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Recommend therapy with albendazole (400 mg&nbsp;orally BID for 10 days) or mebendazole (100 mg&nbsp;orally&nbsp;twice daily&nbsp;for 30 days) is generally inefective.",
"        <sup>",
"         &loz;",
"        </sup>",
"        Doxycycline (200 mg&nbsp;orally daily for six weeks) clears mf for up to 36 months.",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     * Fischer, P, et al. J Infect Dis 1999; 180:1403.",
"     <br>",
"      &bull; Nutman, TB, et al. J Infect Dis 1987; 156:662; Gonzalez, AA, et al. West Indian Med J 1999; 48:231.",
"      <br>",
"       &Delta; Bartholomew CF, et al. Trans R Soc Trop Med Hyg 1978; 72:423.",
"       <br>",
"        &loz; Bregani ER, et al. Trans R Soc Trop Med Hyg 2006; 100:458.",
"        <br>",
"         &sect; Coulibaly YI, et al. N Eng J Med 2009; 361:1448.",
"         <br/>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_35_20028=[""].join("\n");
var outline_f19_35_20028=null;
var title_f19_35_20029="ICD low EF post MI MADIT II";
var content_f19_35_20029=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    ICD improves survival in MADIT II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 256px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier estimates of the probability of survival in the MADIT II trial in 1232 patients who had a myocardial infarction more than 30 days prior to enrollment (and more than three months if bypass surgery was performed) and an LVEF &le;30 percent. The patients were randomly assigned to a prophylactic ICD or conventional medical therapy. The study was prematurely terminated after an average follow-up of 20 months because the ICD significantly reduced all-cause mortality (14.2 versus 19.8 percent for conventional therapy, hazard ratio 0.65, 95 percent CI 0.51 to 0.93). The survival benefit was largely due to a reduction in sudden death.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Moss AJ, Zareba W, Hall WJ, et al. N Engl J Med 2002; 346:877.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_35_20029=[""].join("\n");
var outline_f19_35_20029=null;
var title_f19_35_20030="Sensitivity of CTA for intracranial aneurysm";
var content_f19_35_20030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81565%7ENEURO%2F69728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81565%7ENEURO%2F69728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Sensitivity of CTA for intracranial aneurysms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 306px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The graph shows the increasing sensitivity of CTA with increasing aneurysm size. Points represent the median, and error bars represent the 95 percent confidence limits. Aneurysms greater than 10 mm have been pooled.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: van Gelder, JM. Computed tomographic angiography for detecting cerebral aneurysms: implications of aneurysm size distribution for the sensitivity, specificity, and likelihood ratios. Neurosurgery 2003; 53:597.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    False-positive intracranial aneurysms reported by CTA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 293px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bars represent the number of reported aneurysms of each size from 199 false-positive reports of aneurysms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: van Gelder, JM. Computed tomographic angiography for detecting cerebral aneurysms: implications of aneurysm size distribution for the sensitivity, specificity, and likelihood ratios. Neurosurgery 2003; 53:597.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_35_20030=[""].join("\n");
var outline_f19_35_20030=null;
var title_f19_35_20031="Drug eruption chronology";
var content_f19_35_20031=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DRUG%2F86511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DRUG%2F86511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 514px\">",
"   <div class=\"ttl\">",
"    Chronology of drug eruptions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 494px; height: 338px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Approximate onset and evolution of uncomplicated drug-induced exanthemas with probable T cell-mediated pathophysiology in previously sensitized individuals. The height of the lines reflects acuity, their ends the approximate duration. In newly sensitized individuals, typically mild exanthems develop between the 8th and 12th day (red dashed line).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bircher AJ. Uncomplicated drug-induced disseminated exanthemas. Chem Immunol Allergy 2012; 97:79. Copyright &copy; 2012 S. Karger AG. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_35_20031=[""].join("\n");
var outline_f19_35_20031=null;
